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MDD,	major	depressive	disorder;		
MS,	mass	spectrometry;		
NAA,	N-acetyl-aspartate;		
O,	orthogonal	
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TCA,	tricarboxylic	acid;		
TMA,	trimethylamine;		
TMAO,	trimethylamine-N-oxide;		
UPLC,	ultra	performance	liquid	chromatography	 	
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Abstract		
Metabolic	phenotyping	corresponds	to	the	 large-scale	quantitative	and	qualitative	analysis	of	 the	metabolome	
ie.	 the	 low-molecular	weight	<1KDa	 fraction	 in	biological	 samples,	 and	provides	a	 key	opportunity	 to	 advance	
neurosciences.	 Proton	 nuclear	magnetic	 resonance	 and	mass	 spectrometry	 are	 the	main	 analytical	 platforms	
used	 for	metabolic	 profiling,	 enabling	 detection	 and	 quantitation	 of	 a	wide	 range	 of	 compounds	 of	 particular	
neuro-pharmacological	 and	 physiological	 relevance,	 including	 neurotransmitters,	 secondary	 messengers,	
structural	lipids,	as	well	as	their	precursors	and,	intermediates	and	degradation	products.	Metabolic	profiling	is	
therefore	particularly	indicated	for	the	study	of	central	nervous	system	by	probing	metabolic	and	neurochemical	
profiles	of	the	healthy	or	diseased	brain,	in	preclinical	models	or	in	human	samples.	In	this	review,	we	introduce	
the	analytical	and	statistical	requirements	 for	metabolic	profiling.	Then,	we	focus	on	key	studies	 in	the	field	of	
metabolic	profiling	applied	to	the	characterization	of	genetically	modified	animal	models	and	human	samples	of	
central	 nervous	 system	 disorders.	 We	 highlight	 the	 potential	 of	 metabolic	 profiling	 for	 pharmacological	 and	
physiological	evaluation,	diagnosis	and	drug	therapy	monitoring	of	patients	affected	by	brain	disorders.	Finally,	
we	discuss	the	current	challenges	in	the	field,	including	the	development	of	systems	biology	and	pharmacology	
strategies	 improving	 our	 understanding	 of	 metabolic	 signatures	 and	 mechanisms	 of	 central	 nervous	 system	
diseases.	
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Introduction		
	
While	the	complexity	of	the	central	nervous	system	presents	unique	challenges	for	developing	novel	therapies,	
the	 diagnosis	 of	 CNS	 disease	 currently	 relies	 on	 compiling	 and	 grading	 a	 bunch	 of	 clinical	 symptoms.	 This	 is	
particularly	 valid	 when	 considering	 diseases	 of	 unknown	 etiology	 such	 as	 Alzheimer’s	 disease,	 schizophrenia	
(SCZ)	 or	 autism-spectrum	 disorders	 (ASD).	 One	 limitation	 of	 the	 currently	 available	 diagnosis	 tools	 is	 that,	 in	
most	 cases,	 the	 disease	 has	 to	 be	 well	 established	 for	 a	 clear	 diagnosis,	 even	 though	 early	 therapeutic	
intervention	 is	 crucial	 for	 improving	 prognosis	 of	 CNS	 diseases.	 There	 is	 therefore	 an	 urgent	 need	 for	 the	
development	of	biomarkers	that	can	help	anticipate	diagnosis	even	before	clinical	signs	become	apparent.	This	
will	allow	a	more	targeted	and	effective	treatment	and	also	to	monitor	treatment	efficacy.		
Metabolites	are	both	intermediates	and	endpoints	of	biological	processes.	Their	identity	and	abundance	directly	
reflect	 biological	 perturbations	 originating	 not	 only	 from	 collective	 internal	 variations	 in	 the	 genome,	
transcriptome	 and	 proteome,	 but	 also	 from	 environmental	 cues	 (diet,	 lifestyle,	 drug	 intake	 and	 toxicological	
exposure)	 (Nicholson	et	al.	2002).	Therefore,	an	emerging	 field	of	 investigation	of	 the	central	nervous	 system	
lies	 in	 the	 study	 and	 characterization	 of	 the	 metabolome:	 the	 entire	 complement	 of	 low-molecular	 weight	
chemicals	smaller	than	1	KDa	present	in	a	given	sample.	Among	known	metabolites	of	relevance	in	the	context	
of	 CNS	 study	 lie	 notably	 energetic	 substrates,	 neurotransmitters,	 neurochemicals	 and	 structural	 lipids.	 Large-
scale	 analysis	 of	 the	metabolome	 is	 achieved	 through	 the	 use	 of	metabolomics,	metabonomics	 or	metabolic	
profiling.	 Metabolomics	 was	 originally	 defined	 as	 the	 detailed	 qualitative	 and	 quantitative	 analysis	 of	 the	
metabolites	 present	 in	 complex	 biological	 samples	 (Oliver	 et	 al.	 1998),	 whilst	 metabonomics	 sought	 the	
measurement	of	the	global	metabolic	response	of	living	systems	to	pathological	stimuli	or	genetic	manipulation	
(Nicholson	et	al.	2002;	Nicholson	et	al.	1999).	Nowadays	the	nuances	between	these	two	terms	have	faded	and	
the	 term	metabolic	 profiling	 is	widely	 used.	 Unlike	 genomics,	 transcriptomics	 or	 proteomics	 approaches	 that	
focus	 primarily	 on	 DNA-encoded	 information,	metabolic	 profiling	 provides	 robust	 and	 quantifiable	metabolic	
phenotypes	called	metabotypes	(Gavaghan	et	al.	2000).	Metabotypes	can	be	seen	as	the	intermediary	metabolic	
phenotypes	 existing	 between	 DNA	 variations	 and	 clinical	 disease	 phenotypes	 observed	 in	 animal	 models	 or	
clinical	 samples	 ((Dumas	2012),	 Fig.	1).	Metabolic	profiling	 strategies	deliver	unique	metabolic	 signatures	 that	
are	 characteristic	of	 the	 conditions	under	 scrutiny.	 The	metabolic	 signature	 can	be	established	 in	a	 variety	of	
biological	matrices.	
Alterations	of	normal	brain	functions	can	directly	impact	CSF	or	plasma	composition	in	which	metabolites	are	in	
dynamic	equilibrium	with	intracellular	and	intra-tissular	metabolites.	In	addition,	metabolites	in	biofluids	can	be	
used	to	trace	chemical	 imbalances	at	the	brain	 level	 in	the	case	of	CSF,	or	at	the	systemic	 level	 in	the	case	of	
blood	and	urine.	This	is	key	to	identifying	circulating	and	excreted	markers	related	to	CNS	disease	(i.e.	“distant	
markers”),	which	 can	 be	 useful	 for	 disease	 diagnosis,	 prognosis	 and	 long-term	 treatment	 efficacy	monitoring	
purposes.	In	the	last	decade,	studying	the	metabolome	of	brain	tissue,	cerebrospinal	fluid	(CSF),	plasma,	serum	
or	urine	of	animal	models	and	patients	has	yielded	to	the	 identification	of	metabolic	signature	specific	of	CNS	
disorders	(Fig.	1).		
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In	 this	 review,	 we	 will	 first	 describe	 the	 two	main	 analytical	 techniques	 used	 for	 metabolic	 profiling	 of	 CNS	
conditions:	 proton	 nuclear	magnetic	 resonance	 (1H-NMR)	 spectroscopy	 and	mass	 spectrometry	 (MS).	We	will	
also	discuss	the	importance	of	chemometrics	to	model	metabolic	changes	in	the	brain	and	the	systems	biology	
approaches	 currently	 in	 development	 for	 integration	 of	 metabolic	 data.	 Then,	 we	 will	 highlight	 the	 major	
findings	using	metabolic	profiling	of	CNS	disorders	and	finally	present	the	current	challenges	in	the	field.		
	
METHODOLOGIES	FOR	METABOLIC	PROFILING	AND	PHENOTYING		
	
A	glimpse	on	the	metabolite	subsets	routinely	detected	by	metabolic	profiling	and	phenotyping	
Around	3,000	metabolites	are	reported	in	textbooks	but	this	number	is	largely	underestimated,	as	many	lower	
abundance	 secondary	 metabolites	 remain	 to	 be	 identified	 and	 characterized.	 Several	 metabolites	 are	 of	
particular	pharmacological	relevance	to	study	in	the	context	of	CNS	disorders,	as	up	to	550	metabolites	impact	
human	 pharmacological	 targets	 (Pawson	 et	 al.	 2014).	 Table	 1	 mentions	 metabolites	 that	 behave	 as	
neurotransmitters	or	signaling	molecules	and	their	cognate	receptors	 in	brain.	Most	neurotransmitters	can	be	
quantified	 in	 brain	 tissue	or	 CSF:	 glutamate,	γ-aminobutyric	 acid	 (GABA),	N-acetyl-aspartyl-glutamate	 (NAAG),	
acetylcholine,	 taurine,	 aspartate,	 glycine,	 serotonin,	 dopamine	 as	 well	 as	 their	 precursors:	 acetate,	
choline/phosphatidylcholine,	 glutamine,	 N-acetyl-aspartate	 (NAA),	 tryptophan,	 kynurenines,	 phenylalanine.	
Metabolites	 related	 to	 energy	 metabolism	 are	 also	 quantifiable:	 tricarboxylic	 acid	 (TCA)	 cycle	 intermediates	
(acetate,	 pyruvate,	 citrate,	 α-ketoglutarate),	 glycolysis	 (glucose,	 pyruvate),	 ketone	 bodies	 (acetone,	
acetoacetate,	 β-hydroxybutyrate)	 or	 anaerobic	 metabolism	 (lactate).	 Metabolic	 profiling	 can	 also	 analyse	
osmolytes,	such	as	taurine	and	NAA,	playing	critical	roles	in	the	control	of	cell	volume	and	fluid	balance	in	the	
brain.	Markers	of	neuronal	health	such	as	NAA	and	of	astroglial	health	such	as	second	messenger	isomer	myo-
inositol	can	also	be	quantified.	Lipidomics,	a	specific	branch	of	metabolomics	focusing	on	the	study	of	the	lipid	
fraction,	has	been	applied	to	brain	research	(Piomelli	et	al.	2007).	Neuronal	lipidomics	covers	not	only	structural	
lipids	 (e.g.	 glycerol,	 glycerophosphocholine,	 phosphocholine,	 ethanolamine)	 but	 also	 signaling	 lipids	 (e.g.	
ceramides	 and	 sphingosines),	 phosphatidylinositol	 (PI)	 secondary	 messengers,	 G-protein	 coupled	 receptor	
agonists	 (e.g.	endocannabinoids)	or	 activators	of	nuclear	 receptors	 	 (e.g.	 retinoic	 acid).	Glutathione	and	 lipid-
oxidized	species	resulting	from	radical	attack	of	reactive	oxygen	species	can	also	be	detected,	giving	access	to	
the	oxidative	stress	status	of	brain	samples.	Finally,	metabolites	synthesized	by	gut	microbiota	or	derived	from	
microbial-mammalian	co-metabolism	can	be	observed	 in	various	biofluids	 (for	review,	see	Russell	et	al.	2013).	
These	microbiota-related	metabolites	include:	amines	(dimethylamine;	trimethylamine,	TMA;	trimethylamine-N-
oxide,	TMAO,	detected	by	NMR	and	MS),	phenyacetylglycine	(PAG),	hippurate	or	short	chain	fatty	acids	(acetate,	
propionate	and	butyrate,	typically	by	GC-MS),	indoles,	aromatic	acids	and	cresols,	typically	detected	by	NMR	and	
quantified	by	 LC-MS	 (Russell	 et	 al.	 2013).	 The	use	of	 cross-cutting	metabolomics	 technologies	has	 resulted	 in	
several	 studies	 on	 the	 role	 of	 gut	 microbial	 metabolites	 on	 the	 CNS	 and	 initiated	 a	 paradigm	 shift	 in	
neurosciences,	 as	 bacterial	metabolites	 could	 affect	 immunity	 and	behavior	 (Hsiao	 et	 al.	 2013).	 In	 support	 of	
this,	a	study	showed	that	the	neurotransmitter	GABA	can	be	synthesized	by	bacterial	 isolates	from	the	human	
intestine	 (Barrett	 et	 al.	 2012).	 In	 addition,	 microbiota	 appears	 essential	 to	 modulate	 plasmatic	 levels	 of	 the	
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serotonin	 precursor	 tryptophan	 and	 its	 depletion	 was	 shown	 to	 directly	 impact	 CNS	 serotonergic	
neurotransmission	(Clarke	et	al.	2013).	
	
1H-NMR-based	and	MS-based	metabolomics	
Proton	 nuclear	 magnetic	 resonance	 (NMR)	 spectroscopy	 and	mass	 spectrometry	 (MS)	 are	 the	 key	 analytical	
methods	currently	used	 for	metabolic	profiling	 ((Dunn	et	al.	2011;	Nicholson	et	al.	2002),	Fig.	1).	 1H-NMR	has	
been	predominantly	 used	 for	 CNS	metabolite	 profiling.	However,	NMR	and	MS	detect	 a	 partially	 overlapping	
range	 of	 metabolites	 with	 different	 sensitivity	 and	 sensibility.	 Therefore,	 a	 combined	 platform	 analysis	 is	
recommended	to	increase	metabolic	coverage.	
When	 set	 in	 a	 magnetic	 field,	 the	 nuclei	 of	 a	 molecule	 resonate	 at	 a	 specific	 frequency	 when	 tipped	 by	 a	
radiofrequency	(Beckonert	et	al.	2010;	Beckonert	et	al.	2007).	This	resonance	frequency	is	determined	both	by	
the	magnetic	 field	 intensity	 and	 the	 electronic	 environment	 of	 the	 nuclei	 and	 can	 be	measured	 by	 an	 NMR	
spectrometer.	A	unique	electronic	environment	surrounds	each	atom	of	a	molecule	is	surrounded	by,	therefore,	
each	 recorded	 resonance	 can	 be	 assigned	 to	 a	 specific	 nucleus.	 The	 natural	 abundant	 proton	 (1H)	 is	 the	
preferred	nucleus	for	NMR-based	metabolic	profiling,	although	31P,	13C	and	15N	can	also	be	used.	High	Resolution	
(HR)	 1H-NMR	 provides	 excellent	 spectral	 resolution	 and	 reproducibility	 and	 enables	 detection	 of	metabolites	
above	 the	micromolar	 range.	Owing	 to	 the	 rapidity	of	data	acquisition	 (10	min./sample)	and	 its	 relatively	 low	
cost	 per	 sample,	 1H-NMR	 is	 particularly	 convenient	 for	 high-throughput	 analysis	 of	 liquid	 samples	 (tissue	
extracts,	urine,	plasma,	CSF).	Various	publications	present	standardized	protocols	for	optimal	sampling	and	NMR	
data	 acquisition	 in	 liquid	 phase	 using	 1H-NMR	 (Beckonert	 et	 al.	 2007)	 (Fig.	 1).	 The	 methanol	 chloroform	
extraction	 enables	 the	 simultaneous	 extraction	 of	 both	 lipids	 and	 aqueous	metabolites	 from	a	 single	 sample,	
making	it	well	suited	for	NMR	investigations	of	brain	(Le	Belle	et	al.	2002).	One	advantage	of	NMR	is	that	liquid	
samples	 can	 be	 analyzed	 following	minimal	 sample	 preparation	 limited	 to	 the	 addition	 of	 internal	 standards	
(Beckonert	et	al.	2010;	Beckonert	et	al.	2007):	tetramethylsilane	for	samples	in	organic	solvents	or	trimethylsilyl	
propionate	 for	 aqueous	 samples.	 These	 deuterated	 standards	 are	 used	 for	 calibrating	 the	 chemical	 shifts	
(δ, expressed	in	units	of	parts	per	million,	ppm).	δ	corresponds	to	the	variation	in	resonance	frequency	of	each	
proton	 as	 compared	 to	 the	 standard	 (Fig.	 1).	 The	 development	 of	 magic-angle-spinning	 (MAS)	 1H-NMR	 has	
allowed	 the	 acquisition	 of	 highly	 resolved	 spectra	 directly	 on	 intact	 tissues,	 such	 as	 brain	 tissues	 or	 biopsies	
(Blaise	 et	 al.	 2007;	 Cheng	 et	 al.	 1997;	 Davidovic	 et	 al.	 2011;	 Garrod	 et	 al.	 1999;	 Tsang	 et	 al.	 2005).	 Detailed	
protocols	for	analysis	of	tissues	and	biopsies	in	solid	phase	using	HR	MAS	1H-NMR	are	available	(Beckonert	et	al.	
2010),	with	specific	guidelines	concerning	brain	tissues	(Tsang	et	al.	2005).	1H	HR-MAS	NMR	is	less	reproducible	
compared	to	conventional	liquid	1H-NMR,	but	bypasses	the	extraction	step	that	may	introduce	sample	handling	
and	extraction	yields	variations.	NMR	is	extremely	reproducible	over	5	orders	of	magnitude	and	operates	in	the	
low	µM	range,	accessing	a	large	number	of	metabolic	intermediates	and	endpoints.		
Over	 the	 last	 decade,	 the	 use	 of	 mass	 spectrometry	 (MS)	 for	 metabolic	 profiling	 has	 been	 impulsed	 by	
improvements	 in	 both	 the	 separation	methods	prior	 to	MS	 analysis	 and	 the	 sensitivity	 of	 detectors.	 Time-of-
flight	and	quadrupole	time-of-flight	(ToF	and	qToF)	detectors	are	now	of	sufficient	sensitivity	to	allow	detection	
in	 the	 picomolar	 range.	 The	 type	 of	 chromatography	 used	 as	 a	 separative	 step	 prior	 to	 MS	 orientates	 the	
detection	of	specific	subclasses	of	metabolites	(polar	versus	non-polar,	high	or	low	molecular	weight,	etc…).	Gas	
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chromatography-MS	(GC-MS)	detects	naturally	or	chemically-derivatized	polar	metabolites.	This	includes	amino	
acids,	 organic	 acids,	 amines	 and	 amides	 within	 a	 18-350	 Da	 molecular	 weight	 range	 (e.g.	 ammonium	 to	
cholesterol)	(Dunn	et	al.	2011).	Conversely,	ultra-high-performance-liquid-chromatography-MS	(UPLC-MS)	does	
not	require	derivatization	of	compounds	and	separates	nonpolar	metabolites	within	a	50-1,500	Da	range.	This	
notably	comprises	high-molecular-weight	lipid	species	(e.g.	triglycerides	and	phospholipids)	and	nonpolar	amino	
acids	 (e.g.	 tryptophan,	 the	 branched	 chain	 amino	 acids:	 valine,	 leucine,	 isoleucine)	 (Dunn	 et	 al.	 2011).	Multi-
dimensional	mass	spectrometry-based	shotgun	lipidomics	(MDMS-SL)	uses	a	targeted	platform	for	specific	study	
of	 lipids	 (Han	 et	 al.	 2011).	 Capillary	 electrophoresis−mass	 spectrometry	 (CE−MS)	 detects	 accurately	 ionic	 and	
highly	polar	metabolites	that	may	not	be	easily	detected	by	either	LC	or	GC-MS	methods	(Ramautar	et	al.	2009).	
Liquid	 chromatography	 coupled	 with	 electrochemical	 colorimetric	 array	 detection	 (LCECA)	 separates	
metabolites	 based	 on	 their	 oxidation	 potential	 and	 was	 used	 to	 detect	 metabolites	 involved	 in	 tryptophan,	
purine	and	tyrosine	pathways	(Bird	et	al.	2012;	Kristal	et	al.	2007).		
After	the	separation	step,	the	sample	is	ionized	and	ions	are	separated	by	the	mass	spectrometer	according	to	
their	mass-to-charge	 (m/z)	 ratio.	 In	GC-MS,	 ionization	 is	usually	obtained	by	electron	 impact	 ionization,	which	
fragments	the	analyte,	while	LC-MS	will	use	electrospray	ionization	in	which	the	analyte	is	sprayed	in	droplets	of	
solvent.	The	signals	corresponding	to	the	analytes	are	sensed	by	detectors	and	processed	into	a	spectrum	of	the	
m/z	ratio	of	the	particles	present	(Dunn	et	al.	2011).	One	of	the	strengths	of	mass	spectrometry	is	its	sensitivity,	
however,	the	dynamic	range	of	the	MS	detectors	(103	or	104)	is	often	compensated	by	the	sources	(102	to	103).	
On	the	NMR	or	MS	spectrum,	each	metabolite	is	registered	by	a	unique	combination	of	peaks	(chemical	shift	δ	
for	NMR	and	m/z	ratio	for	MS,	Fig.	1b),	providing	a	fingerprint	specific	to	each	metabolite	and	giving	access	to	
qualitative	 data	 about	 metabolite	 identities.	 There	 is	 however	 a	 bottleneck	 for	 structural	 identification	 in	
untargeted	metabolomics:	metabolites	with	similar	structures	lead	to	signals	overlapping	at	the	same	resonance	
in	 the	NMR	 spectrum,	which	 can	only	be	 resolved	by	using	multidimensional	NMR,	 typically	 1H-1H	and	 1H-13C	
NMR.	 Likewise,	 several	 structures	with	 the	 same	molecular	mass	will	 result	 in	 the	 same	m/z	 ratio	 in	 the	MS	
spectrum,	which	requires	high-resolution	MS	or	MS/MS	to	resolve	ambiguities.	NMR	and	MS	peak	intensities	are	
linearly	related	to	the	relative	abundance	of	the	metabolite	in	the	sample,	providing	quantitative	data.	The	next	
section	introduces	the	statistical	methods	used	in	the	metabolomics	field	to	extract	biological	information	from	
NMR	or	MS	spectra.	
	
Multivariate	analysis	of	spectral	data.	
Biological	samples	display	a	high	biochemical	complexity	related	to	the	coexistence	of	hundreds	or	thousands	of	
distinct	metabolites.	As	a	result,	NMR	and	MS	acquisitions	generate	a	vast	amount	of	data,	 typically	stored	 in	
megavariate	matrices	(n	individuals	<<	k	variables)	(Fig.	1)	(Fonville	et	al.	2010).	Data	analysis	is	a	crucial	step	to	
reduce	data	matrices	and	facilitate	spectral	interpretation	to	identify	markers	predicting	the	class	of	the	sample	
(e.g.	case	vs.	control)	for	a	given	input	(e.g.	metabolic	profile,	Fig.	1)	(Cloarec	et	al.	2005;	Crockford	et	al.	2006;	
Fonville	et	al.	2010).		
To	analyze	metabolomics	data,	many	statistical	users	draw	upon	Principal	Component	Analysis	(PCA),	a	method	
originally	 described	 by	 Pearson	 in	 the	 20’s.	 PCA	 is	 an	 unsupervised	 statistical	 method	 used	 to	 visualize	
differences,	 trends	 and	 relationships	 between	 samples	 and	 variables.	 Avoiding	 a	 priori	 classification	 of	 the	
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samples,	PCA	models	the	directions	of	greatest	variation	in	data,	which	are	named	principal	components	(PC).	
PCA	scores	describe	total	variation	between	individuals	and	allow	detection	of	clusters	within	the	total	variance	
of	the	dataset	and	strong	outliers,	i.e.	individuals	in	the	sample	strongly	deviating	from	the	rest	of	the	dataset.	
PCA	loadings	describe	the	 importance	of	each	variable	responsible	for	variations	between	samples	(Fonville	et	
al.	2010).	Often	in	the	metabolomics	field,	PCA	will	not	have	sufficient	discriminatory	potential	and	will	be	used	
to	deplete	the	datasets	from	outliers	prior	to	a	supervised	analysis	that	will	be	used	to	tackle	subtle	metabolic	
variations.	
As	 a	 supervised	 statistical	method,	 Partial	 Least	 Square	Discriminant	 Analysis	 (PLS-DA)	 integrates	 information	
about	the	class	of	the	samples	(e.g.	disease	vs.	control,	untreated	vs.	treated,	treatment	dose).	This	information	
is	implemented	in	the	model	through	a	dummy	Y	matrix	that	is	added	to	the	X	matrix	of	spectral	data	(Fonville	
et	al.	2010).	PLS-DA	will	model	the	relationships	between	the	variables	(metabolite	peaks)	and	the	class	of	the	
samples,	with	PLS	scores	providing	information	about	class	separation	(e.g.	diseased	or	healthy	class;	Fig.	1)	and	
PLS	loadings	informing	on	variables	responsible	for	separation	(e.g.	metabolites;	Fig.	1).	By	removing	structured	
noise	from	data,	the	development	of	Orthogonal	PLS	(O-PLS)	has	considerably	improved	spectral	interpretation	
and	is	now	widely	used	(Fonville	et	al.	2010).	 
Finally,	PCA	and	PLS	models	are	adequately	validated	at	the	statistical	level	in	terms	of:	i)	goodness-of-fit	to	the	
existing	 data	 (R2	 statistic)	 and	 ii)	 predictive	 ability	 for	 new	 data	 (Q2	 statistic,	 root	 mean	 square	 of	 error	 of	
prediction,	RMSEP).	Both	R2	and	Q2	are	 routinely	used	 in	PLS	modeling,	whereas	RMSEP	 tends	 to	be	used	 for	
other	methods	 (Fonville	 et	 al.	 2010). A	 typical	 7-round	 cross-validation	 is	 applied	 to	 prevent	 overfitting,	with	
1/7th	of	the	samples	being	excluded	from	fitting	the	mathematical	model	in	each	round,	then	being	predicted.	
In	the	PLS	framework	the	R2Y	parameter	estimates	the	goodness-of-fit	of	the	model,	representing	the	fraction	of	
explained	Y-variation,	whereas	Q2Y	summarises	the	predictive	ability	of	the	model,	 ie	the	fraction	of	predicted	
variance	derived	from	cross	validation.	This	led	to	the	implementation	of	several	“rules	of	thumb”,	for	instance	
considering	 that	 a	 model	 with	 a	 Q2Y>0.4	 is	 reliable.	 To	 provide	 more	 systematic	 assessment	 of	 multivariate	
predictive	 significance,	 random	 permutation	 tests	 were	 introduced	 to	 further	 validate	 supervised	 models.	
Permutation	 testing	 is	 typically	 implemented	 by	 removing	 the	 dependence	 between	 explicative	metabolome	
data	(X)	and	class	membership	random	relabeling	of	the	metabolomic	data	and	refitting	supervised	PLS	models.	
After	200-10,000	iterations	of	the	random	permutation	process,	the	empirical	probability	(ie,	empirical	p-value)	
that	the	observed	separation	might	be	due	to	chance	is	calculated	by	comparing	the	model’s	original	Q2Y	to	the	
population	of	Q2Y	fitted	during	the	random	permutation	process. 
To	illustrate	the	use	of	PLS-DA,	we	provide	as	an	example	the	metabolic	profiling	of	brain	tissues	from	the	Fmr1-
KO	mouse	model	of	Fragile	X	Syndrome	(FXS),	the	most	common	inherited	form	of	intellectual	disability	and	first	
genetic	cause	of	autism.	In	this	study,	cortex,	cerebellum,	hippocampus	and	striatum	metabolites	from	Fmr1-KO	
and	 WT	 mice	 were	 profiled	 using	 HR-MAS	 1H	 NMR	 (Davidovic	 et	 al.	 2011).	 Supervised	 O-PLS-DA	 analyses	
generated	 a	 three-dimensional	 score	 plot	 (Fig.	 2A).	 Each	 position	 on	 the	 plot	 represents	 the	 metabolomic	
fingerprint	derived	from	the	NMR	spectrum	of	an	individual	sample.	We	have	shown	that	control	wild	type	(WT)	
brain	samples	segregate	in	distinct	peripheral	regions	of	the	model.	This	strikingly	illustrates	the	anatomical	and	
functional	 differences	 between	 each	 brain	 region	 that	 is	 directly	 reflected	 in	 their	 distinct	metabolic	 content	
(Fig.	 2A).	 Conversely,	 Fmr1-KO	mouse	 brain	 regions	 all	 tend	 to	 project	 towards	 distinct	 areas	 of	 the	model,	
 9 
indicating	a	characteristic	metabolic	signature	in	KO	samples,	distinct	from	the	WT	samples	(Fig.	2A).	The	O-PLS	
coefficients	 are	 represented	 as	 a	 pseudo-spectrum	 to	 highlight	 the	 spectral	 regions	 directly	 interpretable	 as	
metabolites,	most	 responsible	 for	discrimination	between	Fmr1-KO	and	WT	cortical	 samples	 (Fig.	 2B).	On	 the	
plot,	the	colour	scale	indicates	the	intensity	of	the	correlation	to	the	KO	or	WT	class.	This	enabled	to	show	that	
Fmr1-deficiency	is	significantly	associated	in	the	cortex	with	a	decrease	in	GABA,	glutamate,	glutamine,	N-acetyl-
aspartate	and	lactate	and	an	increase	in	acetoacetate	and	lipid-oxidized	species	(mainly	carbonyls,	such	as	CH3-
CH2-CH2-CO-	and	-CH2-CO-)	(Fig.	2B).	For	the	cortical	model,	the	predictive	ability	was	of	61%	(	Q2Yhat	=	0.61).	
This	means	that	based	on	the	metabolic	profile	of	a	given	sample,	the	model	was	able	to	predict	its	WT	or	KO	
class	in	61%	cases.	
	
Pathway-mapping	of	metabolic	signatures		
A	key	perspective	in	metabolic	phenotyping	of	CNS	diseases	remains	the	interpretation	of	metabolic	signatures:	
a	 single	metabolite	 is	unlikely	 to	be	a	biomarker	of	a	CNS	disease,	while	 combinations	of	altered	metabolites	
form	 a	 metabolic	 signature	 of	 the	 disease.	 Systems	 biology	 approaches	 were	 introduced	 to	 highlight	 the	
metabolic	pathways	 that	are	significantly	enriched	 in	 the	metabolic	signature	 (Pontoizeau	et	al.	2011;	Xia	and	
Wishart	2010).	 In	metabolite-set	enrichment	analyses	 (MSEA),	 the	complex	metabolic	pattern	 is	mapped	onto	
existing	 metabolic	 pathways	 compiled	 in	 publicly	 available	 databases	 (Figure	 3A).	 For	 example,	 the	 KEGG	
pathway	 database	 is	 widely	 used	 by	 the	 metabolic	 profiling	 community	 and	 integrates	 metabolic,	 genomic,	
chemical	and	systemic	 functional	 information	 (Kanehisa	et	al.	2012).	The	metabolic	pattern	 is	 then	repeatedly	
tested	for	association	with	each	pathway	in	the	database,	using	enrichment	tests	such	as	Chi2	test	in	the	case	of	
a	qualitative	overrepresentation	analysis	or	 for	a	quantitative	enrichment	analysis	 (Pontoizeau	et	al.	2011;	Xia	
and	Wishart	2010).	The	result	of	the	analysis	is	finally	displayed	in	a	summary	plot,	as	obtained	using	free	online	
resources	such	as	the	MSEA	webserver	(www.msea.ca)	(Xia	and	Wishart	2010).	For	instance,	MSEA	was	used	to	
highlight	significant	alterations	of	D-glutamate	and	D-glutamine	metabolism	and	Glutathione	metabolism,	 (i.e.	
oxidative	stress	response)	in	the	cortex	of	Fragile	X	Syndrome	mouse	model	(Fig.	2C).		
	
KEY	METABOLIC	MARKERS	ASSOCIATED	WITH	CNS	DISEASES		
	
Over	 the	 last	 decade,	 there	 has	 been	 a	 marked	 increase	 in	 the	 number	 of	 studies	 characterizing	 the	
neurochemical	 and	 metabolic	 profile	 of	 murine	 models	 and	 clinical	 samples	 of	 neurological	 disorders.	 To	
summarize	these	numerous	findings,	we	constructed	a	synoptic	table,	providing	an	overview	of	the	key	studies	
using	metabolic	profiling	approaches	to	characterize	animal	models	or	human	samples	with	a	specific	focus	on	
three	classes	of	CNS	diseases:	neurodegenerative,	neurodevelopmental	and	psychiatric	disorders	 (Tab.	2).	We	
then	 highlight	 common	 metabolic	 pathways	 affected	 in	 CNS	 diseases	 by	 performing	 MSEAs	 for	 the	 various	
metabolic	signatures	identified	in	brain	or	CSF	samples	of	each	disease	(Tab.	3).		
	
Neurodegenerative	diseases	
Studies	 in	 preclinical	 models.	 Initial	 studies	 using	 metabolic	 profiling	 to	 study	 CNS	 diseases	 examined	 brain	
extracts	from	two	mouse	models	of	Neuronal	Ceroid	Lipofuscinosis	(NCL),	the	most	prevalent	form	of	paediatric	
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neurodegeneration,	 associated	with	 the	CLN3	 (MIM204200)	 and	CLN8	 (MIM	600143)	 loci	 (Griffin	 et	 al.	 2002;	
Pears	et	al.	2005).	Despite	small	samples	size	(n=5),	metabolic	profiling	revealed	that	both	NCL	models	displayed	
converging	metabolic	abnormalities.	These	abnormalities	were	even	detectable	at	one	month	of	age,	before	the	
animals	 expressed	 the	 neurological	 phenotypes	 (Griffin	 et	 al.	 2002;	 Pears	 et	 al.	 2005).	 MSEA	 highlighted	
alterations	 in	 D-glutamate	 and	 D-glutamine	 metabolism	 (Tab.	 3).	 These	 alterations	 were	 in	 agreement	 with	
previously	 reported	changes	 in	expression	of	genes	 involved	 in	glutamine/glutamate/GABA	metabolism	 in	 the	
Cln3	mouse	model	 (Brooks	et	 al.	 2003).	Analysis	 of	 the	plasma	 from	 the	Mdn	model	 reveals	up-regulation	of	
carbonyl	residues,	mainly	lipid	oxidised	species	CH2-CH2-CH2	and	a	decrease	in	lactate	and	glucose,	indicative	of	
increased	oxidative	stress	and	compromised	energetic	metabolism	(Pears	et	al.	2005).	More	recently,	the	mouse	
model	 of	 PHARC	 (polyneuropathy,	 hearing	 loss,	 ataxia,	 retinosis	 pigmentosa,	 and	 cataract)	 disorder	
(MIM612674)	was	studied	using	LC	MS-based	metabolic	profiling	(Blankman	et	al.	2013).	The	disease	is	caused	
by	mutations	 in	 the	 poorly	 characterized	 serine	 hydrolase	 alpha/beta-hydrolase	 domain-containing	 (ABHD)12	
enzyme.	Profiling	of	brain	 lipids	 from	the	Abhd12	KO	mouse	 revealed	a	massive	 increase	 in	a	 rare	set	of	very	
long	chain	lysophophatidylserines	lipids	(7	up-regulated	species)	previously	reported	as	pro-inflammatory	lipids	
behaving	as	Toll-like	receptor	2	activators.	This	increase	appears	from	2	months	of	age	and	is	concomitant	with	
microglial	activation	coupled	to	auditory	and	motor	defects	that	resemble	the	behavioral	phenotypes	of	human	
PHARC	patients.	These	studies	illustrate	how	metabolic	profiling	can	be	used	to	better	understand	the	molecular	
basis	of	human	disorders	 in	mouse	models.	Furthermore,	 these	studies	performed	 in	 rodent	models	strikingly	
highlight	 that	metabolic	abnormalities	are	detectable	even	before	neurological	or	 cognitive	defects	arise,	 and	
across	various	biological	matrices	such	as	brain	tissues	or	biofluids.	
	
Alzheimer’s	 disease	 (AD,	 MIM104300).	 AD	 represents	 the	 most	 common	 form	 of	 progressive	 dementia	
characterized	by	accumulation	of	neurotoxic	plaques	(accumulation	of	abnormally	folded	beta	amyloid	peptide)	
and	 tangles	 (aggregates	of	 the	microtubule-associated	protein	Tau)	 in	 the	brain	of	patients	 (Frost	et	al.	2014;	
Karran	et	al.	2011).	Metabolic	profiling	of	AD	preclinical	and	clinical	samples	has	received	considerable	attention	
from	the	scientific	community	over	the	past	years	(Tab.	2).		
Metabotyping	of	the	brain	of	two	mouse	models	of	AD,	CRND8	and	Tg2576	mice,	identified	common	markers,	
with	 noticeable	 decreases	 in	 glutamate,	 N-acetylaspartate,	 creatine,	 gamma-aminobutyric	 acid	 and	
phosphocholine	(Lalande	et	al.	2014;	Salek	et	al.	2010).	Our	MSEA	reveals	that	the	metabolism	of	glutamate	is	
significantly	affected	(Tab.	3).	Lipid	profiling	identified	a	complementary	set	of	dysregulated	metabolites	in	the	
CRND8	animal	model	(Lin	et	al.	2013).	Notably,	alterations	in	eicosanoids	(including	7	prostaglandins)	as	part	of	
arachidonic	acid	metabolism	were	observed,	 suggestive	of	 the	neuroinflammation	 that	 is	also	observed	 in	AD	
patients	 (Latta	et	al.	2014).	However,	 these	preclinical	 findings	await	 replication	 in	patient	 samples	since	only	
one	 study	 profiled	 the	 metabolome	 of	 post	 mortem	 cortical	 samples	 from	 AD.	 The	 approach	 reached	 94%	
accuracy	for	disease	prediction,	however,	no	metabolite	assignment	was	performed	(Graham	et	al.	2013).		
Studies	 using	 different	 metabolomic	 platforms	 identified	 common	 AD	 markers	 in	 cerebrospinal	 fluid	 from	
patients.	The	metabolism	of	catecholaminergic	neurotransmitters	(dopamine,	epinephrine	and	norepinephrine)	
is	tightly	linked	to	phenylalaline	and	tyrosine	metabolism	and	MSEA	(Tab.	3)	 indicates	convergent	variations	in	
these	 pathways	 (Czech	 et	 al.	 2012).	 Importantly,	 the	 severity	 of	 the	 disease	 was	 correlated	 with	 decreased	
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noradrenaline	 (Kaddurah-Daouk	 et	 al.	 2011b)	 and	 increased	 levels	 of	 vanillylmandelic	 acid,	 a	 degradation	
product	 of	 xanthine	 and	 dopamine	 (Kaddurah-Daouk	 et	 al.	 2013b).	 Also,	MSEA	 (Tab.	 3)	 highlighted	 that	 two	
independent	studies	indicated	alterations	in	methionine	metabolism	(Czech	et	al.	2012;	Ibanez	et	al.	2012).		
Finally,	 three	 studies	 performed	on	 independent	 cohorts	 identified	 a	 common	 lipid	 signature	 in	 serum	of	 AD	
patients	characterized	by	a	decrease	in	several	lipid	classes,	notably	sphingomyelins	(Han	et	al.	2011;	Oresic	et	
al.	2011).	One	study	even	showed	that	sphingomyelins	and	ceramides	species	 levels	correlated	with	cognitive	
performance	in	AD	patients	(Han	et	al.	2011).	More	recently,	a	study	profiled	the	plasma	lipid	profile	of	a	cohort	
of	 cognitively	 normal	 elderly	 adults	 and	 followed	 the	 same	 individuals	 four	 years,	 at	 a	 time	 by	 which	 some	
individuals	 had	 developed	 AD	 (Kanekiyo	 et	 al.	 2014).	 The	 authors	 identified	 a	 metabolic	 signature	 of	 ten	
plasmatic	 lipids	 that	 were	 predictive	 of	 the	 occurrence	 of	 mild	 cognitive	 impairment	 or	 Alzheimer's	 disease	
within	a	2–3	year	timeframe	with	over	90%	accuracy.	These	data	support	the	involvement	of	dyslipidemia	in	AD	
and	 are	 in	 line	with	 the	 abundant	 literature	 on	 the	APOE4	 variant	 as	 a	major	 risk	 allele	 for	 AD	 that	 leads	 to	
disruption	in	sterol	and	sphingolipid	metabolism	(Kanekiyo	et	al.	2014).		
	
Huntington’s	disease	(HD,	MIM143100).	HD	is	an	autosomal	dominant	progressive	neurodegenerative	disorder	
caused	 by	 abnormal	 trinucleotidic	 repeats	 expansions	 in	 the	 Huntingtin1	 (HD1)	 gene	 leading	 to	 motor	
impairment,	 cognitive	 decline	 and	dementia.	HD	 is	 studied	 in	 various	mouse	models	 and	 the	 3-nitropropionic	
acid	 intoxication	 rat	model	 in	 which	 neurodegeneration	 of	 striatal	 spiny	 neurons	mimics	 the	 human	 disease.	
Brains	of	the	R6/2	HD	mouse	model	and	the	rat-treatment	model	display	common	metabolic	anomalies	(Tsang	et	
al.	2009;	Tsang	et	al.	2006)	(Tab.	2).	Strikingly,	in	both	models,	GABA,	choline	and	NAA	are	decreased	and	MSEA	
predicts	significant	striatal	alterations	 in	glutamate	metabolism	as	detected	by	MSEA	(Tab.	3).	These	metabolic	
results	would	need	to	be	further	confirmed	 in	post	mortem	 samples	of	HD	patients.	Urine	and	plasma	of	R6/2	
mice	display	metabolic	variations	associated	with	altered	energy	metabolism,	notably	in	glucose	levels	(Tsang	et	
al.	2006).	Importantly,	plasmatic	hyperglycemia	is	observed	in	the	two	models	and	seems	indicative	of	defective	
systemic	 glucose	 metabolism,	 reflecting	 metabolic	 modifications	 in	 peripheral	 tissues	 in	 addition	 to	 specific	
neurodegenerative	 changes.	 Strikingly,	 similar	 hyperglycemia	 was	 obtained	 when	 comparing	 plasmas	 from	
asymptomatic	 and	 early	 symptomatic	 humans	 and	mice,	 indicating	 a	 clear	 translation	 of	 plasmatic	metabolic	
biomarkers	(Tsang	et	al.	2009;	Tsang	et	al.	2006;	Underwood	et	al.	2006).	An	increased	level	of	glucose	in	plasma	
is	in	line	with	previous	hypothesis	that	HD	is	associated	with	diabetes	(Farrer	1985).	Also,	increased	markers	of	
lipids	 beta-oxidation	 (glycerol	 an	 dethylene	 glycol)	 and	 alterations	 in	 lactate	 levels	 are	 compatible	 with	 a	
systemic	 deregulation	 of	 energy	 expenditure,	 which	 may	 be	 related	 to	 cachexia	 symptoms	 observed	 in	 HD	
patients	(Underwood	et	al.	2006).	A	study	identified	branched	chain	amino	acids	(valine,	 leucine,	isoleucine)	as	
plasmatic	markers	of	HD,	whose	levels	correlate	with	disease	progression	and	abnormal	triplet	repeat	expansion	
size	in	the	HD1	gene	(Mochel	et	al.	2007).	These	data	collectively	suggest	that	systemic	deregulations	of	glucose,	
neurotransmitters	 and	 BCAA	metabolism	 contribute	 to	 HD	 and	 that	 the	 corresponding	metabolites	 represent	
potential	clinical	biomarkers	that	could	be	useful	to	monitor	disease	progression.	
	
Parkinson’s	 Disease	 (PD,	 MIM168600).	 PD	 is	 the	 second	 most	 common	 neurodegenerative	 disorder	 after	
Alzheimer’s	disease,	 resulting	 from	the	neurodegeneration	of	dopaminergic	neurons	 in	substantia	nigra.	PD	 is	
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associated	 with	 motor	 problems	 (ataxia,	 tremor)	 and	 dementia.	 PD	 is	 mostly	 idiopathic	 but	 can	 also	 be	 of	
genetic	 origin.	 Two	 metabolic	 profiling	 studies	 of	 PD	 patients	 reveal	 decreased	 plasmatic	 levels	 of	 the	
antioxidant	uric	acid,	the	final	product	of	purine	metabolism	(Bogdanov	et	al.	2008;	Johansen	et	al.	2009).	One	
study	showed	that	levels	of	uric	acid	are	negatively	associated	with	PD	and	disease	progression	(Bogdanov	et	al.	
2008;	 Johansen	et	al.	2009).	Also	 levels	of	glutathione	were	 increased	strongly	 reinforcing	 the	contribution	of	
oxidative	 stress	 to	 HD	 (Bogdanov	 et	 al.	 2008;	 Johansen	 et	 al.	 2009).	 Based	 on	 the	 plasmatic	 variations	 of	 9	
metabolites	mostly	involved	in	purine	metabolism,	one	study	could	predict	whether	the	PD	was	secondary	to	a	
genetic	mutation	or	of	 idiopathic	origin	 (Johansen	et	al.	2009).	The	model	built	 reached	85.7%	sensitivity	and	
80%	specificity,	suggesting	the	possibility	to	develop	future	PD	diagnosis	approaches	based	on	plasma	metabolic	
profiling.		
	
Motor	 neuron	 diseases.	Motor	 neuron	 diseases	 form	 a	 heterogeneous	 set	 of	 neurodegenerative	 disorders	
affecting	both	upper	and	 lower	motor	neurons,	which	 trigger	progressive	muscle	atrophy.	The	most	 common	
forms	 of	MND	 are	 amyotrophic	 lateral	 sclerosis	 (ALS,	MIM105400)	 and	 spinocerebellar	 ataxia	 (SCA).	 Various	
brain	 regions	of	 the	mouse	model	 of	 the	motor	 neuron	disease	 Spinocerebellar	Ataxia	 3	 (SCA3,	MIM109150)	
were	 profiled	 (Griffin	 et	 al.	 2004).	 This	 study	 showed	 that	 SCA3	 cerebellum	 is	 the	 most	 affected	 region,	
paralleling	the	strong	cerebellar	deficits	observed	in	SCA3	patients	(Seidel	et	al.	2012).	SCA3	cerebellum	displays	
altered	 glutamate	 metabolism	 as	 detected	 by	 MSEA	 (Tab.	 3)	 and	 these	 alterations	 precede	 detection	 of	
neurological	deficits.	These	data	now	await	further	confirmation	in	clinical	samples	of	SCA	patients.		
A	study	involved	95	MND-affected	patients,	85%	being	affected	by	ALS,	and	identified	a	metabolic	signature	in	
CSF	that	could	predict	MND	with	78.9%	sensitivity	and	76.5%	specificity	(Blasco	et	al.	2014).	MSEA	revealed	that	
the	discriminating	metabolites	were	related	to	branched	chain	amino	acids	metabolism,	as	well	as	phenylalanine	
and	tyrosine	metabolism	(Tab.	3).	One	study	studied	the	CSF	of	ALS	patients	(Blasco	et	al.	2013)	and	identified	
alterations	 in	pyruvate	and	ketone	body	metabolism	as	revealed	by	MSEA	(Tab.	3).	 Interestingly,	 these	results	
found	 considerable	 echo	 as	 another	 study	 that	 highlighted	 systemic	 disruption	 of	 energy	metabolism	 in	 ALS,	
with	altered	plasmatic	levels	of	acetate,	acetone	and	beta-hydroxybutyrate	(Kumar	et	al.	2010).		
	
Psychiatric	conditions		
Depression.	 The	 etiology	 and	 pathophysiology	 of	 Major	 Depressive	 Disorder	 (MDD,	 unipolar	 depression,	
MIM608516)	and	bipolar	disorder	(BD,	MIM125480),	two	major	chronic	and	debilitating	psychiatric	conditions,	
remain	mostly	unknown	despite	the	identification	of	many	genetic	and	epigenetic	factors	that	may	predispose	
to	the	development	of	these	diseases.	Metabolic	profiling	of	samples	from	patients	affected	by	these	disorders	
has	contributed	to	a	better	understanding	of	the	globally	deregulated	neuronal	pathways.	A	study	on	prefrontal	
cortex	post	mortem	 samples	 from	bipolar	patients	 reports	 specific	metabolic	changes	associated	with	notable	
increases	 in	 glutamate,	 myo-inositol	 and	 creatine	 (Lan	 et	 al.,	 2009).	 Importantly,	 treatment	 of	 rats	 with	 the	
mood-stabilizing	agent	lithium	decreases	the	glutamine/glutamate	ratio,	myo-inositol	and	creatine	levels	in	the	
brain	(McLoughlin	et	al.	2009),	strongly	suggesting	that	lithium	treatment	reverses	the	metabolic	signature	in	BD	
patients.	The	prefrontal	cortex	of	the	chronic	unpredictable	mild	stress	(CUMS)	depression	rat	model	displayed	
lower	 levels	of	 isoleucine	and	glycerol	 in	combination	with	higher	 levels	of	beta-alanine	and	NAA	 (Chen	et	al.	
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2014),	indicative	of	Alanine	metabolism	dysregulations	(Tab.	3).	Metabolic	profiling	of	CSF	samples	reveals	that	
remitted	 MDD	 patients	 display	 a	 metabolic	 signature	 significantly	 different	 from	 the	 controls	 or	 currently	
depressed	patients	(Kaddurah-Daouk	et	al.	2012).	The	absence	of	a	significant	metabolic	signature	in	currently	
depressed	MDD	patients	might	originate	from	the	high	inter-individual	clinical	heterogeneity	in	these	patients,	
combined	with	small	sample	size	(Kaddurah-Daouk	et	al.	2012).	However,	this	study	identified	that	in	depressed	
MDD	patients,	lower	levels	of	serotonin	precursor	tryptophan	and	higher	levels	of	both	5-hydroxyindoleacetate	
(a	 serotonin	 catabolite)	 and	 4-hydroxy-3-methoxyphenyl	 glycol	 (a	 dopamine	 catabolite)	 are	 correlated	 with	
more	severe	 symptoms	of	anxiety	 (Kaddurah-Daouk	et	al.	2012).	 Systemic	biomarkers	of	depressive	disorders	
were	 identified	 in	 serum	 samples	 from	bipolar	 patients	 (Sussulini	 et	 al.	 2009)	 and	MDD	patients	 (Paige	 et	 al.	
2007).	These	studies	revealed	specific	metabolic	signatures	involving	variations	in	lipids,	neurotransmitters	and	
energy-related	metabolites	(lactate,	acetate	for	BD	and	3-hydroxybutanoic	acid	for	MDD).	Further	studies	using	
bigger	 cohorts	may	contribute	 to	 the	development	of	metabolomics-based	biomarkers	 for	 future	diagnosis	of	
various	forms	of	depressive	disorders.	
	
Schizophrenia	 (SCZ,	MIM181500).	SCZ	 is	 a	 common	disorder	with	a	 lifetime	prevalence	of	approximately	1%.	
The	 disease	 is	 characterized	 by	 a	myriad	 of	 symptoms:	 psychotic	 symptoms	 (hallucination	 and	 delusion)	 and	
severe	cognitive	symptoms	(inappropriate	emotional	responses,	disordered	thinking	and	concentration,	erratic	
behavior)	as	well	as	social	and	occupational	deterioration	(Fornito	and	Bullmore	2014).	In	a	seminal	study,	the	
prefrontal	cortex	of	schizophrenic	patients	presented	deficiencies	 in	D-glutamine	and	D-glutamate	metabolism	
(MSEA,	 Tab.	 3)	 and	 more	 generally	 in	 neurotransmitters	 biosynthesis	 (Prabakaran	 et	 al.	 2004).	 This	 was	
accompanied	by	a	strong	increase	in	lactate	and	in	lipids,	suggesting	alterations	in	pyruvate	metabolism	(MSEA,	
Tab.	3)	in	the	schizophrenic	brain	(Prabakaran	et	al.	2004).	Another	study	also	detected	alterations	in	pyruvate	
metabolism	in	the	CSF	of	SCZ	patients,	with	a	specific	increase	in	glucose	coupled	to	decreased	signals	for	lactate	
and	 acetate	 (Holmes	 et	 al.	 2006).	 To	 further	 substantiate	 the	 relevance	of	 studying	CSF	metabolic	 profiles	 to	
predict	disease,	metabolic	profiling	of	patients	prodromal	for	psychosis	-which	is	usually	considered	as	the	early	
clinical	 stage	 prior	 to	 onset	 of	 psychosis	 and	 schizophrenia-	 showed	 that	 36%	 of	 these	 patients	 displayed	
metabolic	 profiles	 characteristic	 of	 schizophrenia	 patients	 (Huang	 et	 al.	 2007).	 This	 suggests	 that	 detectable	
metabolic	 alterations	 precede	 the	 occurrence	 of	 overt	 psychosis,	 making	 it	 possible	 to	 identify	 prodromal	
markers.	
Systemic	 markers	 were	 identified	 in	 the	 plasma	 of	 drug-naive	 SCZ	 patients,	 highlighting	 a	 decrease	 in	
polyunsaturated	fatty	acids	PUFAs	(n3,	n6	and	n9	fatty	acid	families),	in	energy	substrates	(lactate,	acetoacetate,	
glucose)	and	uric	 acid	 (Cai	et	 al.	 2012).	 This	hypo-uremia	was	also	detected	 in	 the	plasma	of	an	 independent	
cohort	 of	 SCZ	 patients	 (Yao	 et	 al.	 2010a;	 Yao	 et	 al.	 2010b).	 Uric	 acid	 being	 the	 main	 plasmatic	 antioxidant,	
decreased	 levels	 in	 biofluids	 of	 SCZ	 patients	 is	 indicative	 of	 increased	 susceptibility	 to	 oxidative	 stress,	
corroborating	several	studies	in	animal	models	and	patients	(Emiliani	et	al.	2014).	Finally,	several	gut	microbial	
metabolites	such	as	hippurate	and	trimethylamine	presented	altered	levels	in	the	urine	of	SCZ	patients	(Cai	et	al.	
2012).	This	 suggests	 that	deregulations	of	 the	gut	microbiome	may	participate	 to	SCZ	pathophysiology	and	 to	
other	neurological	conditions	(Collins	et	al.	2012;	Cryan	and	Dinan	2012).		
The	metabolic	signature	of	antipsychotic	treatment,	the	principal	neuroleptic	drugs	used	to	treat	schizophrenia	
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was	also	studied.	In	rat	brain,	most	of	the	antipsychotics	and	mood	stabilizing	drugs	induce	an	increase	in	NAA	
and	modulated	glucose	metabolism,	neurotransmitters	(notably	glutamate)	and	secondary	messengers	inositols	
(McLoughlin	et	al.	2009),	these	pathways	being	affected	in	the	brain	(Prabakaran	et	al.	2004)	and	CSF	(Holmes	et	
al.	 2006;	 Huang	 et	 al.	 2007)	 of	 SCZ	 patients	 (Tab.	 2).	 Metabolic	 profiling	 of	 SCZ	 patients	 before	 and	 after	
antipsychotic	treatment	was	performed	in	brain	samples,	CSF	and	plasma.	Metabolic	markers	were	identified	in	
post	mortem	brain	 tissue	 from	drug-naïve	 schizophrenic	patients,	 corresponding	 to	amino	acid	and	glutamine	
metabolism	normalized	by	 lifetime	antipsychotic	 treatment	 (Chan	et	al.	2011).	One	of	 the	key	 findings	 is	 that	
patients	responding	to	atypical	antipsychotics	(50%	of	patients)	present	a	normalization	of	their	CSF	metabolic	
profiles	well	before	clinical	improvements	were	observed	(Chan	et	al.	2011;	Holmes	et	al.	2006). Conversely,	no	
normalization	 of	 the	 CSF	 metabolic	 signature	 was	 observed	 in	 patients	 in	 whom	 treatment	 had	 not	 been	
initiated	 at	 the	 first	 psychotic	 episode	 (Holmes	 et	 al.	 2006).	 This	 study	 highlights	 at	 the	metabolic	 level	 the	
importance	 of	 early	 therapeutic	 intervention	 for	 schizophrenic	 patients.	 In	 two	 independent	 studies	 using	
different	 metabolomics	 platforms	 plasmatic	 metabolic	 signature	 of	 schizophrenia	 was	 normalized	 upon	
treatment	with	the	antipsychotic	risperidone	(Cai	et	al.	2012;	Yao	et	al.	2010a).	One	study	studied	in	details	the	
plasmatic	lipidic	profiles	of	SCZ	patients	before	and	after	3	weeks	treatment	with	the	antipsychotics	olanzapine,	
risperidone	 or	 aripiprazole	 (Kaddurah-Daouk	 et	 al.	 2007).	 Olanzapine	 and	 risperidone	 were	 shown	 to	 have	
strong	modifying	effects	on	plasmatic	lipid	composition,	with	notable	increases	in	triacylglycerol	and	decrease	in	
fatty	acids	(Kaddurah-Daouk	et	al.	2007).	This	is	consistent	with	the	strong	metabolic	effects	reported	for	these	
two	drugs	(Ballon	et	al.	2014).	
These	promising	 results	would	need	to	be	confirmed	 in	 larger	cohorts	 in	order	 to	derive	markers	of	diagnosis	
and	monitoring	of	treatment	efficacy	in	plasma	or	urine	of	SCZ	patients.	
	
Neurodevelopmental	disorders	
Autism	 spectrum	 disorders	 (ASD,	 MIM209850).	 ASD	 constitute	 a	 family	 of	 complex	 neurodevelopmental	
disorders.	ASD	patients	display	 impairments	 in	social	 interactions	and	communication,	 restricted	 interests	and	
increased	 anxiety.	 ASD	 originates	 from	 a	 combination	 of	 genetic	 and	 environmental	 factors.	 Notably,	 strong	
correlations	between	maternal	 infection	during	pregnancy	and	ASD	incidence	have	been	described	(Knuesel	et	
al.	2014).	The	maternal	immune	activation	(MIA)	mouse	model	of	environmentally-triggered	ASD	is	obtained	by	
poly(I:C)s	 injections	 in	 pregnant	 mice	 that	 induce	 an	 IL6-mediated	 maternal	 immune	 response	 affecting	
neurodevelopment	of	progeny,	mimicking	 in	utero	viral	 infection	(Meyer	2014).	The	plasma	of	this	MIA	model	
was	studied	using	metabolomics	(Hsiao	et	al.	2013).	This	study	showed	that	levels	of	the	microbial-mammalian	
co-metabolite	4-ethylphenylsulfate	(4-EPS)	were	increased	40	times	in	the	plasma	of	MIA	mouse	model	of	ASD	
(Hsiao	et	al.	2013).	This	finding	is	particularly	relevant	as	4-EPS	was	shown	to	induce	anxiety-related	behavioral	
anomalies	in	wild	type	mice	(Hsiao	et	al.	2013).	Moreover,	a	probiotic	bacteria,	Bacteroides	fragilis,	restores	4-
EPS	levels	to	normal	and	reverse	anxiety-linked	behaviors	in	MIA	mice	(Hsiao	et	al.	2013).	This	study	illustrates	
how	 metabolic	 profiling	 contributes	 to	 elucidate	 the	 molecular	 trigger	 of	 altered	 behavior	 in	 MIA	 ASD	 and	
strengthen	the	link	between	altered	microbiota	and	ASD.	
This	link	is	also	supported	by	the	identification	of	several	altered	urinary	metabolites	of	microbial	origin	in	ASD	
patients.	 Notably,	 variations	 in	 the	 microbial-mammalian	 co-metabolites:	 dimethylamine,	 hippurate	 and	
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phenylacetylglutamine	were	observed	in	one	cohort	of	ASD	patients	(Yap	et	al.	2010).	Variations	in	the	urinary	
levels	of	microbial-mammalian	 co-metabolites	were	also	 identified	 in	an	 independent	 cohort	of	ASD	patients:	
hippurate,	 one	 of	 its	 precursors	 3-hydroxyphenylacetate	 and	 co-metabolite	 3-hydroxyhippurate,	 as	 well	 as	
indole-3-acetate	 (Emond	 et	 al.	 2013).	 These	 studies	 performed	 in	 ASD	 mouse	 models	 and	 clinical	 samples	
strongly	support	a	 recent	 theory	 involving	gut	microbial	deregulations	 in	neurological	conditions	 (Collins	et	al.	
2012;	Cryan	and	Dinan	2012).		
	
Down	syndrome	(DS,	MIM190685).	DS	 is	the	most	frequent	genetic	cause	of	 intellectual	deficiency	caused	by	
triplication	 of	 chromosome	 21.	 Serum	metabolic	 profiling	 of	 first-trimester	 pregnant	women	 identified	 novel	
markers	 for	 the	 prediction	 of	 fetal	 DS	 (Bahado-Singh	 et	 al.	 2013)	 earlier	 than	 regular	 tests	 and	 without	
amniocentesis.	An	OPLS-DA	model	derived	from	serum	levels	of	3-hydroxybutyrate,	3-hydroxyisovalerate	and	2-
hydroxybutyrate	reached	75%	sensitivity	and	86.2%	predictivity.	Metabolic	variations	in	DS	placenta	and	foetus	
contribute	to	the	specific	serum	metabolic	signature	observed	in	pregnant	mothers.	Some	of	these	metabolites	
are	 known	 to	be	 associated	with	oxidative	 stress	 (2-hydroxybutyrate),	 poor	myelination	 and	neurotoxicity	 (3-
hydroxyisovalerate	and	3-hydroxybutyrate),	which	are	phenotypic	characteristics	associated	with	DS.	 
	
Rett	Syndrome	(RS,	MIM	312750).	RS	is	the	major	genetic	cause	of	profound	intellectual	disability	 in	females,	
due	to	the	inactivation	of	the	X-linked	MECP2	gene	encoding	the	transcription	factor	methyl	cytosine	phosphate	
dinucleotide	guanine	binding	protein	(Weng	et	al.	2011).	1H-NMR-based	metabolic	profiling	of	brain	extracts	of	
the	Mecp2-null	mouse	reveals	alterations	in	D-glutamine	and	glutamate	metabolism	((Viola	et	al.	2007),	MSEA	
Tab.	3).		
	
Fragile	X	Syndrome	(FXS,	MIM300624).	FXS	is	the	most	common	form	of	inherited	intellectual	disability	and	the	
most	 frequent	 identified	 genetic	 cause	 for	 autism-spectrum	disorders	 since	 15-20%	of	 FXS	 patients	meet	 the	
criteria	for	ASD	(Penagarikano	et	al.	2007).	A	comprehensive	metabolomic	study	on	various	brain	regions	of	the	
FXS	 mouse	 model,	 the	 Fmr1-knockout	 mouse	 (Mientjes	 et	 al.	 2006),	 has	 revealed	 region-specific	 metabolic	
signature,	 with	 cerebellum	 and	 cortex	 being	 the	 most	 affected	 regions	 (Davidovic	 et	 al.	 2011).	 This	 study	
indicated	 that	 various	 neurotransmitters,	 including	 GABA,	 glutamate,	 taurine	 and	 acetylcholine	 and	 their	
precursors	are	perturbed	 in	 the	FXS	mouse	model.	MSEA	analysis	 revealed	 that	D-glutamine	and	D-glutamate	
metabolism	as	well	as	arginine	and	proline	metabolism	were	significantly	affected	((Davidovic	et	al.	2011),	Tab.	
1).	Also,	increased	levels	of	lipid-oxidised	species	were	detected	in	the	cortex	of	Fmr1-KO	mice	(Davidovic	et	al.	
2011),	indicative	of	increased	oxidative	stress,	in	line	with	previous	observations	(Bechara	et	al.	2009;	de	Diego-
Otero	et	al.	2009).	Moreover,	this	metabolic	profile	has	striking	overlap	with	the	patterns	detected	in	the	mouse	
model	of	RS	(Viola	et	al.	2007),	another	syndrome	leading	to	intellectual	disability.	
	
IDENTIFICATION	OF	COMMON	METABOLIC	MARKERS	OF	CNS	DISEASES	
The	rise	in	the	number	of	CNS-related	metabolomic	studies	provides	a	unique	opportunity	to	cross-examine	the	
metabolic	 signatures	associated	 to	 the	above-mentioned	disorders	and	converge	 towards	 the	 identification	of	
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common	 markers,	 strongly	 suggesting	 that	 common	 mechanisms	 can	 directly	 contribute	 to	 co-morbid	
pathologies	with	different	clinical	manifestations	(Tab.	2&3).		
	
CNS	perturbations	directly	detected	in	the	brain.	NAA	is	the	second	most	abundant	molecule	in	the	brain	after	
glutamate	 (Moffett	 et	 al.	 2007)	 and	 its	 levels	 are	 decreased	 in	 a	 number	of	 CNS	 conditions	 (Tab.2).	NAA	 is	 a	
neuronal	 osmolyte,	 as	 well	 as	 a	 precursor	 for	 both	 lipid	 and	 myelin	 synthesis	 in	 oligodendrocytes	 and	 a	
precursor	 of	 the	 neurotransmitter	 N-acetylaspartylglutamate	 (NAAG).	 MSEA	 of	 the	 metabolic	 signatures	
determined	 in	 various	 neurological	 conditions	 (Tab.	 3)	 reveals	 terms	 linked	 to	 biosynthesis	 of	 amino-acid	
neurotransmitters	 such	 as	 “D-glutamine	 and	 D-glutamate	 metabolism”,	 “Alanine,	 aspartate	 and	 glutamate	
metabolism”	or	“Glycine,	serine	and	threonine	metabolism”	are	recurrently	enriched	in	the	metabolic	signature	
of	CNS	disorders	(Tab.	3).	Deregulations	in	brain	energy	metabolism	are	consistently	observed	in	CNS	conditions,	
as	revealed	by	MSEA	of	metabolic	signatures	which	highlights	alterations	in	energetic	substrates	(Tab.	3)	As	an	
example,	lactate	levels	are	affected	in	pathologies	as	diverse	as	AD,	HD,	PD,	SCA,	CLN,	BD,	SCZ	or	FXS	(Tab.	2).	
Lactate	 is	 normally	 a	 breakdown	 product	 of	 glycolysis,	 however,	 several	 studies	 now	 suggest	 that	 lactate	 is	
metabolized	by	the	intact	brain	in	an	activity-dependent	manner	and	has	a	direct	neuroprotective	effect	(Wyss	
et	al.	2011).	MSEA	of	CSF	metabolic	signatures	of	ALS	and	schizophrenia	present	the	terms	“Gluconeogenesis”	or	
“Pyruvate	metabolism”	 (Tab.	 3).	 Brain	 energy	 supply	 is	 required	not	only	 for	 basal	 cellular	metabolism	which	
results	 in	 ATP	 fuelling	 for	 basic	 biological	 reactions,	 but	 also	 for	 the	 synthesis	 and	 degradation	 of	
neurotransmitters,	 preservation	 of	 membrane	 ionic	 gradients	 and	 maintenance	 of	 secondary	 messengers	
cascades	 and	 may	 have	 drastic	 consequences	 on	 neuronal	 functions	 as	 hypothesized	 for	 schizophrenia	
(Prabakaran	et	al.	2004)	and	Fragile	X	Syndrome	(Davidovic	et	al.	2011).		
	
Systemic	metabolic	dysregulations	in	CNS	disorders.	Given	that	metabolic	signatures	for	various	CNS	diseases	
partially	overlap	 (Tab.	2),	 relying	on	a	 single	biomarker	 to	predict	a	 specific	CNS	disease	 is	not	 sufficient.	One	
may	more	rely	on	combinations	of	biomarkers,	which	may	define	altered	metabolic	pathways	and	will	be	more	
precise	 than	a	single	biomarker	 to	detect	and	monitor	 the	disease.	Metabolomic	models	 for	prediction	of	 the	
diseases	 are	 built	 on	 several	 metabolites,	 illustrating	 the	 necessity	 to	 use	 global	 metabolic	 signatures	 that	
guarantee	the	specificity	of	the	diagnosis.	Importantly,	systemic	biomarkers	detectable	in	urine,	plasma	or	CSF	
would	 be	 the	most	 relevant	 for	 translation	 to	 human	 and	 several	 studies	 demonstrate	 the	 great	 potential	 of	
metabolic	 not	 only	 for	 diagnosis	 but	 also	 for	 treatment	 assessment.	 As	 such,	 pilot	 studies	 on	 CSF	 of	
schizophrenic	and	depressed	patients	reveal	that	metabotyping	predicts	the	disease	status	for	a	given	sample,	
as	well	as	treatment	outcome	(Holmes	et	al.	2006;	Huang	et	al.	2007;	Kaddurah-Daouk	et	al.	2011a;	Kaddurah-
Daouk	et	al.	2007;	Lan	et	al.	2009;	Prabakaran	et	al.	2004).	This	is	particularly	relevant	for	psychiatric	conditions	
of	unknown	etiology	since,	up	to	date,	diagnosis	rely	on	psychocognitive	tests	and	no	biochemical	or	genetic	test	
is	 available	 for	 these	 diseases.	 By	 systematic	 cross-examination	 of	 metabolic	 pathway	 enrichment	 in	 brain-
related	metabolic	phenotyping	studies,	it	is	anticipated	that	metabolomics	will	lead	to	a	shift	from	disease-based	
classifications	towards	mechanism	or	pathway-based	mechanisms.	
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FUTURE	CHALLENGES	AND	UNDDRESSED	QUESTIONS.	
Have	 covered	 several	 aspects	 of	 modern	 high-throughput	 metabolic	 phenotyping	 in	 the	 CNS	 field,	 it	 is	
anticipated	that	many	basic	neuroscience	findings	will	be	made	with	these	technologies.	However	this	is	a	fast-
evolving	field	and	several	unaddressed	questions	represent	future	challenges.		
	
Cell	 type	 and	 organelle-specific	 metabolomics.	 So	 far,	 metabolic	 profiling	 studies	 have	 focused	 on	 global	
changes	 in	CNS-specific	metabolites	 (brain,	 CSF)	 or	 systemic	markers	 (plasma,	 urine)	 to	predict	 diseases.	One	
current	 challenge	 in	 the	 metabolomics	 field	 would	 be	 to	 move	 to	 the	 study	 of	 cell-type	 specific	 metabolic	
variations.	For	example,	primary	cultures	of	neurons	or	astrocytes	of	animal	models	of	CNS	diseases	could	be	
used	 to	 detect	 cell-type	 specific	 metabolic	 variations	 which	 could	 help	 determine	 whether	 the	 global	 brain	
changes	originate	more	from	one	cell	type	or	another	and	help	refine	more	targeted	treatments.	A	recent	study	
combined	whole-cell	 patch	 clamp	 recording	 and	 capillary	 electrophoresis	 (CE)-mass	 spectrometry	 (MS)-based	
metabolomics	to	gather	information	at	the	single-cell	level	on	ex	vivo	rat	brain	thalamic	slices	(Aerts	et	al.	2014).	
Patch-clamp	recording	yielded	information	on	the	electrophysiological	properties	of	the	selected	cell.	The	patch-
clamp	pipette	was	 then	used	 to	 retrieve	a	portion	of	 the	cytoplasm	of	 the	 recorded	cells,	providing	sufficient	
substrate	 for	 metabolomic	 analysis	 using	 CE-MS.	 Combining	 morphological,	 electrophysiological	 data	 and	
neurochemical	of	each	recorded	cell	profile	enabled	to	accurately	determine	their	very	nature:	glutamatergic	or	
GABAergic	inhibitory	neurons	or	astrocytes.	This	study	shows	that	adjacent	thalamic	nuclei	produce	dramatically	
different	neurotransmitter	 profiles,	 reflecting	 their	 unique	neuronal	 populations.	 The	 current	development	of	
induced	pluripotent	 cells	 (iPS	 cells)	 from	CNS	disease-affected	patient’s	 fibroblasts,	 that	have	 the	 capacity	 for	
differentiation	 into	specific	neuronal	or	glial	 lineages	offers	great	promises	 in	 the	 field	 (Orlacchio	et	al.	2010).	
Such	 approach	 would	 also	 provide	 insights	 in	 the	 neuron/glial	 cell	 co-metabolome.	 Importantly,	 the	
development	 of	 high-throughput	 methodologies	 for	 metabolomic	 analysis	 would	 enable	 systematic	 drug	
screening	on	neuronal	or	glial	cultures	systems,	as	performed	on	cancer	cell	lines	and	primary	cultures	(Tiziani	et	
al.	2011).	In	addition,	metabolic	profiling	will	provide	information	on	cell-specific	secondary	effects	of	drugs	and	
help	 refine	 treatments.	Another	 challenge	 lies	 in	 the	metabolic	 profiling	of	 smaller	 cellular	 compartments	 via	
organelle	 metabolomics.	 Nerve	 terminals	 preparations	 such	 as	 synaptoneurosomes	 could	 be	 analyzed	 to	
determine	the	specific	 levels	of	neurotransmitters	 in	these	structures	 in	CNS	pathological	conditions.	Also,	the	
study	 of	membrane-enriched	 preparation	 could	 lead	 to	 the	 accurate	 determination	 of	 the	 lipids	 composition	
with	different	electrical	properties.		
	
Pharmacometabonomics.	 	 Another	 key	 perspective	 has	 been	 introduced	with	 the	 accurate	 prediction	 of	 the	
response	 to	 a	 treatment	based	on	predose	metabolic	 profiling	 (Clayton	et	 al.	 2009;	Clayton	et	 al.	 2006).	 This	
personalized	medicine	approach	was	coined	“pharmacometabonomics”	and	opens	new	avenues	for	metabolic	
research	in	CNS	diseases.	Following	the	first	studies,	which	focussed	on	predicting	the	response	of	rats	(Clayton	
et	al.	2006)	and	humans	(Clayton	et	al.	2009)	to	a	sub-toxic	dose	of	acetaminophen	using	naïve	(pre-dose)	urine	
samples,	several	papers	were	subsequently	published	in	various	contexts,	and	in	particular,	in	the	management	
of	Major	 Depressive	 Depression	 (MDD)	 (Kaddurah-Daouk	 et	 al.	 2013a;	 Kaddurah-Daouk	 et	 al.	 2011a).	 In	 the	
latest	double-blind	pharmacometabolomic	study	(Kaddurah-Daouk	et	al.	2013a),	the	authors	tested	whether	the	
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baseline	 metabolic	 profile	 of	 a	 patient	 with	 MDD	 can	 predict	 patient	 response	 to	 treatment	 with	 the	
antidepressant	 sertraline	 over	 1-	 to	 4-	 weeks.	 In	 this	 study,	 Kaddurah-Daouk	 and	 co-workers	 identified	 that	
lower	plasma	levels	of	branched	chain	amino	acids	(BCAAs)	correlate	with	positive	treatment	outcomes.	These	
results	on	BCAAs	in	CNS	disorders	are	very	timely	as	Newgard	and	co-workers	determined	that	supplementation	
in	BCAA	was	associated	with	anxiety-like	phenotypes	in	the	mouse	(Coppola	et	al.	2013).	Remarkably,	Novarino	
et	 al.	 demonstrated	 that	 mutations	 in	 branched	 chain	 amino	 acid	 keto	 dehydrogenase	 kinase	 gene	 (BCKDK)	
were	 associated	with	 a	 particular	 form	 of	 heritable	 autism	with	 epilepsy	 (Novarino	 et	 al.	 2012).	 These	 three	
studies	suggest	that	BCAAs	(and	potentially	other	metabolites)	play	a	prominent	role	in	CNS	disorders	and	that	
metabolic	 profiles	 can	 predict	 treatment	 outcomes	 in	 the	 clinical	 setting.	 These	 recent	 developments	 in	
pharmacometabonomics	also	open	new	perspectives	 in	patient	stratification	for	CNS	disorders.	Future	studies	
should	involve	larger	cohorts	of	patients	to	identify	common	and	specific	prognostic	biomarkers	for	each	class	of	
drugs.	CNS	diseases	clinical	practice	is	compromised	by	noncompliance	of	patients	to	treatment	mostly	because	
of	non-responsiveness	or	side	effects.	In	this	context,	metabolomics	could	be	a	valuable	tool	to	stratify	patients	
into	 responding	 and	 non-responding	 groups	 to	 determine	 the	 best	 treatment	 based	 on	 predose	 metabolic	
profiling.	 Such	 approach	 would	 directly	 improve	 personalized	 and	 optimized	 treatment	 for	 patients	 and	
therefore	maximize	treatment	outcome.  
	
Genetic	determinants	of	metabotypes.	A	new	research	area	in	metabolomics	corresponds	to	the	identification	
of	 genetic	 determinants	 for	metabolic	 phenotypes	 (i.e.,	 metabotypes).	 By	 acquiring	 genome-wide	 genotyping	
and	metabolic	phenotyping	data	in	parallel,	 it	 is	now	possible	to	determine	quantitative	trait	 loci	for	metabolic	
traits	 (mQTL,	 i.e.	 polymorphisms	 determining	 metabolite	 abundance)	 in	 genetic	 intercrosses	 in	 rodents	 or	
segregating	 human	 populations	 (Dumas	 et	 al.	 2007;	 Suhre	 et	 al.	 2011a;	 Suhre	 et	 al.	 2011b).	 Using	 a	 similar	
approach,	brain	metabolic	profiles	could	be	correlated	to	DNA	polymorphisms	and	haplotypes	to	identify	brain-
specific	mQTLs,	which	should	result	in	a	better	understanding	of	the	genetic	regulation	of	brain	metabotypes;	at	
least	 in	 animal	 models.	 The	 affordability	 of	 next	 generation	 sequencing	 methods	 in	 combination	 with	
corresponding	metabolomic	data,	would	enable	 in	the	near	future	mQTL	applications	to	highlight	susceptibility	
SNPs	and	CNVs	for	neurological	diseases	of	complex	etiology,	such	as	schizophrenia,	bipolar	disorder	or	autism-
spectrum	disorders.	 An	 integrated	metabolomic	 and	 genomic	 approach	was	 used	 to	 study	 selective	 serotonin	
reuptake	inhibitor	(SRI)	treatment	outcome	in	patients	with	major	depressive	disorder	(MDD)	(Ji	et	al.	2011).	This	
study	 shows	 that	 glycine	 levels	 are	 negatively	 correlated	 to	 SRI	 treatment	 outcome,	 indicating	 that	 discrete	
sequence	 variations	 in	 genes	 encoding	 enzymes	 involved	 in	 glycine	 metabolism	 might	 contribute	 to	 the	
metabolomic	findings.	 In	a	subsequent	genome-wide	association	study	(GWAS),	the	same	team	identified	SNPs	
for	six	genes	encoding	enzymes	in	glycine	biosynthesis	were	selectively	associated	to	SRI	response:	for	instance	
SNP	rs10975641	in	the	glycine	decarboxylase	(GLDC)	gene	was	associated	with	treatment	outcome	phenotypes	
(Ji	et	al.	2012).	These	two	studies	 illustrate	 that	GWAS	 identify	SNPs	and	candidate	genes	validating	metabolic	
markers	and	pathways	previously	 identified	by	metabolomics.	 It	 is	also	anticipated	that	with	the	availability	of	
DNA	methylation	chips,	epigenome-wide	association	studies	between	“-C-phosphate-G-“	(CpG)	methylation	sites	
and	metabolomic	traits	will	shed	a	new	light	on	the	epigenetic	regulation	of	metabolic	patterns	in	CNS	diseases.	
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Integration	 of	 biological	 and	 signalling	 networks	 regulating	 brain	 metabotypes.	Metabolite-set	 enrichment	
analysis	 algorithms	 represent	 a	 real	 progress	 in	 terms	 of	 unbiased	 assessment	 of	 the	 coherence	 of	metabolic	
signatures	 at	 the	 pathway	 level,	 which	 is	 not	 always	 the	 case,	 as	 exemplified	 in	 Tab.	 2	 presenting	metabolic	
signatures,	which	do	not	yield	significant	enrichment	in	metabolic	pathways	(Tab.	3).	MSEA	approaches	remain	
limited	 because	 (i)	 they	 test	 metabolite	 for	 membership	 in	 metabolic	 pathways	 using	 arbitrary	 pathway	
definitions.	(ii)	they	do	not	provide	any	understanding	of	the	regulation	of	metabolic	patterns,	for	instance	how	
disease	 causing	 genes	 (if	 known)	mechanistically	 contribute	 to	 the	 observed	metabolic	 signature.	 In	 order	 to	
address	 these	 challenges,	 we	 used	 interactome-based	 systems	 biology	 strategies,	 by	 coupling	 protein-protein	
interaction	networks	and	signaling/transduction	pathways	to	metabolic	pathways	(Davidovic	et	al.	2011).	A	novel	
alternative	 strategy,	 integrated	metabolome	and	 interactome	mapping”	 (iMIM)	was	devised	and	 implemented	
(Figure	 3A).	 Using	 iMIM,	 metabolic	 phenotypes	 are	 directly	 mapped	 onto	 a	 compilation	 of	 protein-protein	
interaction	 (ppi),	 metabolite-enzyme	 interactions	 and	 ligand-receptor	 interactions	 networks	 extracted	 from	
literature	and	databases.	Since	the	human	interactome	is	estimated	to	have	650,000	ppi	(Stumpf	et	al.	2008),	the	
analysis	of	 the	topology	of	 the	resulting	network	has	become	necessary	to	 identify	key	proteins	regulating	the	
metabolic	signatures	associated	with	disease-causing	genes.	To	identify	key	proteins	(i.e.	the	busiest	proteins)	in	
the	interaction	network,	shortest	paths	between	causal	genes	and	the	downstream	metabolic	consequences	are	
first	computed,	then	network	statistics	such	as	the	‘pivotal	betweenness’	(Davidovic	et	al.	2011;	Freeman	1977)	
are	used	to	highlight	the	busiest	intersections	in	the	network	(i.e.,	the	proteins	shared	by	several	shortest	paths).	
These	 central	 proteins	 correspond	 to	 key	 regulators	 relaying	 the	 signal	 between	 the	 causal	 genes	 and	 the	
metabolites.	Using	iMIM	approach,	we	identified	the	regulatory	proteins	controlling	the	metabolic	signature	of	
Fragile	X	Syndrome	in	the	brain,	and	identified	links	with	Alzheimer’s	disease	and	oxidative	stress	(Davidovic	et	
al.	 2011).	 It	 is	 anticipated	 that	new	developments	and	 refinements	 in	 the	 iMIM	methodology	will	 consistently	
improve	the	reliability	and	the	predictive	power	of	the	output	predictions.	Notably,	one	perspective	involves	the	
introduction	of	weighting	factors	 integrating	other	“omics”	data	 in	the	metabolic	network.	For	example,	taking	
into	account	variations	in	transcriptomic	or	proteomic	profiles	could	help	refining	the	bioinformatic	predictions	
of	 key	 proteins	 and	 key	 pathways	 and	 increase	 biological	 relevance	 towards	 the	 studied	 disease.	 Also,	
interactome-mapping	of	metabolic	phenotypes	could	be	easily	amenable	to	the	study	of	monogenic	disorders	or	
polygenic	disorders	and	should	help	understanding	metabolomic	signatures	of	CNS	conditions.		
	
Conclusions	and	perspectives	
The	 study	 of	 brain	 metabolism	 and	 CNS	 diseases	 has	 recently	 witnessed	 a	 series	 of	 shifts,	 related	 to	 the	
development	 of	 state-of-the-art	 methods	 in	 spectrometry,	 statistics	 and	 systems	 biology.	 Metabolomics	 has	
now	been	used	for	over	fifteen	years	in	CNS	research	and	has	enabled	key	advances	in	terms	of	identification	of	
CNS	disease	signatures,	showing	that	brain	metabolism	is	not	restricted	to	neurotransmitter	synthesis,	and	that	
intermediate	metabolism	variations	contribute	to	generating	complex	brain	disorder	phenotypes.	However,	the	
detailed	mechanistic	understanding	of	the	generation	of	these	complex	metabolic	patterns	remains	a	challenge.	
The	integration	of	genetic,	epigenetic,	interaction	and	signaling	networks	to	understand	the	regulation	of	brain	
metabolic	 biochemistry	 will	 undoubtedly	 lead	 to	 a	 better	 understanding	 of	 CNS	 disease	 mechanism.	 The	
translation	 of	 pharmacometabonomic	 approaches	 identifying	 predictive	 circulating	 markers	 for	 treatment	
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efficacy	 into	 the	 CNS	 disease	 clinic	 is	 one	 of	 the	 key	 challenges,	 which	 could	 significantly	 influence	 clinical	
monitoring	of	patients	and	therapeutic	decisions.	
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Figures	and	tables	
	
Figure	1.	Typical	metabolic	phenotyping	workflow	
A.	For	metabolic	profiling	of	CNS	conditions,	human	cohorts	need	to	be	adequately	powered	(typically	n=30	to	
1,000	 individuals),	 whereas	 for	 animal	 models	 n=5-10	 per	 condition	 should	 be	 sufficient.	 B.	 Biofluids	 (urine,	
plasma,	CSF,	 saliva)	or	 intact	brain	 samples	or	extracts	are	 collected	 in	a	 standardized	manner	 (biopsies,	post	
mortem	 samples,	 surgery	 resection).	 C.	 Spectral	 data	 are	 acquired	 on	 each	 sample	 using	 Nuclear	 Magnetic	
Resonance	or	Mass	 Spectrometry,	 followed	by	 computer-assisted	data	 import,	 preprocessing	 and	databasing,	
resulting	 in	 a	 megavariate	 matrix	 summarizing	 the	 metabolite	 peaks	 (variables,	 1	 to	 k)	 for	 each	 sample	
(individuals,	 1	 to	 n).	D.	 Extensive	 pattern	 recognition	multivariate	 statistical	 analysis	 of	 spectral	 data	 enables	
classification	and/or	prediction	of	diseased	and	control	samples	based	on	statistical	scores	 (left	graph).	Model	
loadings	 are	 derived	 to	 determine	 the	 metabolites	 whose	 variations	 maximize	 the	 discrimination	 between	
diseased	and	healthy	individuals.	Orthogonal	Partial	Least	Square	Discriminant	Analysis	(O-PLS-DA)	models	can	
be	represented	as	a	pseudo-spectrum	(right	graph).	Correlation	to	the	class	of	the	sample	(diseased	or	healthy)	
is	 given	 by	 color-scaled	 covariance	 values.	 Positive	 model	 coefficients	 correspond	 to	 higher	 metabolite	
concentrations	 in	 the	 diseased	 condition,	 whereas	 negative	 model	 coefficients	 are	 associated	 with	 higher	
metabolite	 concentrations	 in	 healthy	 condition.	 Significantly	 affected	 metabolites	 represent	 candidate	
biomarkers	of	the	disease,	here	m1	to	m3.	
	
Figure	 2.	Metabolomics	 in	 CNS	 research	 by	 example:	 the	metabolic	 signature	 of	 Fragile	 X	 Syndrome	 in	 the	
brain	of	its	mouse	model.		
A.	 Following	 initial	 metabolic	 profiling	 of	 four	 brain	 anatomical	 regions	 (cortex,	 cerebellum,	 striatum	 and	
hippocampus)	by	1H	HR-MAS	NMR	spectroscopy,	the	metabolic	variation	related	to	brain	region	and	FXS	disease	
status	 was	 analysed	 using	 orthogonal	 partial	 least	 square	 discriminant	 analysis.	 The	 3D	 O-PLS-DA	 score	 plot	
shows	an	efficient	 segregation	of	 the	eight	 groups	of	 brain	 samples,	 based	on	anatomical	 region	and	disease	
status.	B.	To	highlight	the	metabolites	responsible	for	the	FXS	signature	in	cortical	samples,	the	O-PLS-DA	model	
loadings	 were	 represented	 as	 a	 pseudo-spectrum	 plot.	 Positive	 model	 coefficients	 correspond	 to	 higher	
metabolite	 concentrations	 in	 KO	 animals,	 whereas	 negative	 model	 coefficients	 are	 associated	 with	 higher	
metabolite	concentrations	in	WT	animals.	Adapted	from	(Davidovic	et	al.	2011).	
	
Figure	3.	Systems	biology	strategies	to	integrate	metabolomic	data.	
A.	Metabolite-Set	Enrichment	Analysis.	Metabolites	that	are	significantly	affected	by	a	disease	form	a	complex	
metabolic	 pattern,	 which	 can	 be	 difficult	 to	 interpret.	 Using	 previous	 knowledge	 about	 metabolic	 pathways	
compiled	 in	 a	 database,	 the	 complex	 metabolic	 pattern	 is	 then	 mapped	 onto	 the	 metabolic	 pathways.	 The	
metabolic	 pattern	 is	 repeatedly	 tested	 for	 association	with	 each	 pathway	 in	 the	 database,	 using	 enrichment	
tests	 such	as	Χ2	 test	 in	 the	 case	of	a	qualitative	overrepresentation	analysis,	or	 for	a	quantitative	enrichment	
analysis	 (Pontoizeau	 et	 al.	 2011;	 Xia	 and	 Wishart	 2010).	 The	 result	 of	 the	 analysis	 if	 finally	 displayed	 in	 a	
summary	 plot,	 as	 obtained	 using	 free	 online	 resources	 such	 as	 the	MSEA	webserver	 (www.msea.ca,	 (Xia	 and	
Wishart	 2010)).	B.	 Integrated	Metabolome	and	 Interactome	Mapping. :	 a	 strategy	 to	 navigate	 the	underlying	
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signalling	networks	and	understand	metabolic	signatures.	Disease-causing	candidate	genes	are	put	into	relation	
with	 patterns	 of	 significant	 metabolites	 via	 protein-protein	 and	 metabolite-protein	 interactions.	 The	 iMIM	
network	 helps	 visualizing	 the	 physical	 molecular	 interactions	 between	 any	 given	 causal	 gene	 and	 any	 given	
downstream	metabolite	through	multiple	paths,	 involving	one	or	several	 intermediary	proteins	when	the	gene	
does	not	encode	an	enzyme,	a	 transporter,	a	 receptor,	or	more	generally,	a	protein	binding	metabolites.	This	
visualization	is	implemented	using	graph	models	in	which	the	nodes	correspond	to	biomolecular	entities:	genes,	
proteins	and	metabolites,	whereas	their	physical	interactions	(binding,	metabolic	reactions)	are	encoded	by	the	
edges.	 In	 iMIM,	 network	 metrics	 are	 then	 used	 to	 define	 shortest	 paths	 and	 pivotal	 proteins	 between	
metabolites	and	disease-causing	genes. One	strategy	to	efficiently	rank	these	proteins	is	to	use	the	betweenness	
(b(v),	 (Freeman	 1977)).	 The	 betweenness	 corresponds	 to	 a	measure	 of	 the	 proportion	 of	 the	 shortest	 paths	
going	through	a	given	node.	Proteins	with	high	b(v)	are	predicted	to	be	pivotal	proteins	in	the	network.	Finally,	
interactome-wide	permutation	tests	are	performed	in	order	to	assess	the	statistical	significance	of	the	resulting	
network.	
	
Table	 1.	 Examples	 of	 pharmacologically	 active	metabolites	 and	 their	 cognate	 receptors	 of	 relevance	 in	 CNS	
disorders.		
Each	 metabolite	 is	 provided	 with	 database	 identifiers	 to	 enable	 direct	 consultation	 of	 several	 metabolic	
databases:	 KEGG	 (http://www.genome.jp/kegg/compound/),	 Human	 Metabolome	 Database	 (HMDB:	
http://www.hmdb.ca/)	or	PubChem	(http://pubchem.ncbi.nlm.nih.gov/)	to	retrieve	information	on	structure	or	
biosynthesis	 of	 the	 compound	 of	 interest.	 Lists	 of	 genes	 encoding	 the	 different	 receptors	 are	 provided	 to	
illustrate	the	diversity	of	the	receptors	that	can	accommodate	a	single	ligand.	
	
Table	2.	Synoptic	of	findings	from	key	metabolomic	studies	defining	metabolic	signatures	of	CNS	diseases.		
	
Table	3.	Metabolic	pathway	enrichment	in	brain	and	CSF	metabolic	signatures	of	CNS	diseases.		
A	pathway	meta-analysis	was	performed	using	metabolite	lists	compiled	in	Table	1	by	metabolite	set	enrichment	
analysis	(MSEA)	based	on	the	webserver	www.msea.ca	(Xia	and	Wishart	2010)	to	highlight	significantly	affected	
metabolic	pathways	in	each	CNS	condition.	Only	pathways	showing	significant	enrichment	are	presented.	
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Metabolite KEGG	  ID HMDB	  ID PubChem	  ID Receptor	  official	  human	  gene	  symbol Receptor	  class
Neurotransmitters 5-­‐Hydroxytryptamine	   C00780 HMDB00259 5202 HTR1A/B/D/E/F,	  HTR2A/B/C,	  HTR3A/B/C/D/E,	  HTR4,	  HTR5A,	  HTR6,	  HTR7 5-­‐Hydroxytryptamine	  receptors
Acetylcholine C01996 HMDB00895 187 CHRM1,	  CHRM2,	  CHRM3,	  CHRM4,	  CHRM5,	   Acetylcholine	  receptors,	  Muscarinic
CHRNA1/2/3/4/5/6/7/9/10,	  CHRNB1/2/3/4,	  CHRND,	  CHRNE,	  CHRNG Acetylcholine	  receptors,	  Nicotinic
Adenosine C00212 HMDB00050 60961 ADORA1,	  ADORA2A/B,	  ADORA3 Adenosine	  receptors
Adrenaline C00788 HMDB00068 5816 ADRA1A/B/D,	  ADRA2A/B/C,	  ADRB1/2/3 Adrenergic	  receptors
Noradrenaline C00547 HMDB00216 439260
Dopamine C03758 HMDB00073 681 DRD1/2/3/4/5 Dopamine	  receptors
GABA C00334 HMDB00112 119 GABRA1/2/3/4/5/6,	  GABRB1/2/3,	  GABRG1/2/3,	  GABRD,	  GABRE,	  	  GABRQ GABAA	  receptors
GABBR1/2 GABAB	  receptors
GABRR1/2/3 GABAC	  receptors
Glutamate C00217 HMDB03339 23327 GRIA1/2/3/4,	  GRIK1/2/3/4/5,	  GRIN1/2A/2B/2C/2D/3A/3B Glutamate	  receptors,	  Ionotropic
GRM1/2/3/4/5/6/7/8 Glutamate	  receptors,	  Metabotropic
Glycine	   C00037 HMDB00123 750 GLRA1/2/3/4,	  GLRB Glycine	  receptors
Melatonin C01598 HMDB01389 896 MTNR1A/AB Melatonin	  receptors
Phosphates ATP C00002 HMDB00538 5957 P2RX1/2/3/4/5/6/7 P2X	  receptors,	  transmitter-­‐gated	  channels
ADP C00008 HMDB01341 6022 P2YR1/12/13 P2Y	  receptors,	  G-­‐protein-­‐coupled
ATP C00002 HMDB00538 5957 P2RY2/11
UDP C00015 HMDB00295 6031 P2RY6
UTP C00075 HMDB00285 6133 P2RY2/4
UDP-­‐glucose C00029 HMDB00286 53477679 P2RY14
Inositol	  triphosphate C00081 HMDB00189 8583 ITPR1/2/3 Inositol	  triphosphate	  receptors
Lipids Leukotriene	  B4 C02165 HMDB01085 5280492 LTB4R1/R2 Leukotriene	  receptors
Lysophosphatidic	  acid C00681 HMDB07853 3950 LPR1/2/3/4/5/6 Lysophospholipid	  receptors
Sphingosine-­‐1-­‐phosphate C06124 HMDB00277 5353956 S1PR1/2/3/4/5
Leukotriene	  B4 C02165 HMDB01085 5280492 PPARA Peroxisome	  proliferator	  activated	  receptor	  α
5-­‐Hydroxyeicosatetraenoic	  acid C04805 HMDB11134 5280733
Unsaturated	  fatty	  acids FA0103 N/A N/A
Prostaglandin	  I2 C01312 HMDB01335 5282411 PPARD Peroxisome	  proliferator	  activated	  receptor	  δ
Unsaturated	  fatty	  acids FA0103 N/A N/A
5-­‐Hydroxyeicosatetraenoic	  acid C04805 HMDB11134 5280733 PPARG Peroxisome	  proliferator	  activated	  receptor γ
9-­‐Hydroxyoctadecadienoic	  acid C14767 HMDB10223 5282945
13-­‐Hydroxyoctadecadienoic	  acid C14762 HMDB06939 6443013
Prostaglandin	  J2 C05957 HMDB02710 5280884
Prostaglandin	  D C00925 HMDB00693 53477714 PTGDR/DR2 Prostanoid	  receptors
Prostaglandin	  E C00584 HMDB01220 5280360 PTGER1/ER2/ER3/ER4
Prostaglandin	  F1 C05442 HMDB00937 5280794 PTGFR
Arachidonoylethanolamine C10203 HMDB32696 5281706 CNR1/2 Cannabinoid	  receptors
2-­‐Arachidonoylglycerol C10521 HMDB34127 5281804
Disease Samples	  details	   Reference Number	  of	  samples Analytical	  platform Metabolites
NEURODEGENERATIVE	  
DISORDERS
Mdn	  mouse	  model	   Griffin	  et	  al.	  2002 brain/plasma n=5	  per	  group HR	  1H-­‐NMR Brain	  UP:	  beta-­‐hydroxybutyrate,	  taurine,	  glutamate,	  CH2CH2CH2	  lipids	  DOWN:	  
creatine,	  glutamine,	  gamma-­‐aminobutyric	  acid	  Plasma	  UP:	  CH2CH2CH2	  lipids	  DOWN:	  
lactate,	  CH3-­‐CH2	  lipids,	  glucose
Cln3	  mouse	  model Pears	  et	  al.,	  2005 brain n=5	  per	  group HR	  1H-­‐NMR UP:	  glutamate,	  myo-­‐inositol,	  creatine	  	  DOWN:	  gamma-­‐aminobutyric	  acid,	  lactate,	  
taurine,	  N-­‐acetyl-­‐aspartate	  
Cln3	  mouse	  model	  brain Griffin	  et	  al.,	  2005 brain n=5	  per	  group HR	  1H-­‐NMR UP:	  glutamate,	  myo-­‐inositol,	  creatine	  	  DOWN:	  gamma-­‐aminobutyric	  acid,	  lactate,	  
taurine,	  N-­‐acetyl-­‐aspartate	  
PHARC Abhd12	  mouse	  model Blankman	  et	  al.,	  2013 brain n=3-­‐5	  per	  group LC	  MS phosphatidylserine	  (2	  sp.	  up;	  2	  sp.	  down),	  lysophosphatidylserine	  (7	  sp.	  up),	  
phosphatidylglycerol	  (2	  sp.	  up;	  1	  sp.	  down),	  	  lysophosphatidylinositol	  (1	  sp.	  up;	  1	  sp.	  
down)
CRND8	  mouse	  model	   Lin	  et	  al.,	  2013 brain n=6	  per	  group LC-­‐MS hippurate,	  salicylurate,	  prostaglandin	  E1/E3/B1/H2/FF2beta/A2/F1alpha	  and	  
derivatives,	  16-­‐hydroxy-­‐2,12-­‐dimethoxypicrasa-­‐2,12-­‐diene-­‐1,11-­‐dione,	  5-­‐
hydroxyeicosatetraenoic	  acid,	  leukotriene	  A4,	  6-­‐phospho-­‐D-­‐gluconate,	  9-­‐oxononanoic	  
acid,	  androsterone,	  glucuronide,	  mannitol,	  11beta-­‐17-­‐Dihydroxy-­‐6alpha-­‐methylpregn-­‐
4-­‐ene-­‐3,20-­‐dione,	  dehydrovomifoliol,	  D-­‐glucuronate,	  oleandolide,15S-­‐hydroxy-­‐11-­‐oxo-­‐
5Z,9Z,13E,17Z-­‐prostatetraenoic	  acid,	  annabidiolic	  acid,	  4-­‐heptyloxybenzoic	  acid,	  5-­‐
oxo-­‐1,2-­‐campholide
Tg2576	  mouse	  model Lalande	  et	  al.,	  2014 brain n=5	  per	  group HR	  1H-­‐NMR DOWN:	  glutamate,	  	  N-­‐acetylaspartate,	  myo-­‐inositol,	  creatine,	  gamma-­‐aminobutyric	  
acid,	  phosphocholine	  
human	  post	  mortem	   Graham	  et	  al.,	  2013 brain n=15	  controls	  n=15	  patients UPLC-­‐QTOF-­‐MS Unassigned	  metabolites
human	  post	  mortem	   Kaddurah-­‐Daouk	  et	  al.	  2011 CSF n=15	  controls	  n=15	  patients LCECA	  HPLC UP:	  5-­‐hydroxytryptophan,	  methoxy-­‐hydroxyphenyl-­‐glycol,	  methoxy-­‐
hydroxymandelate	  	  	  	  	  DOWN:	  norepinephrine,	  3-­‐methoxytyramine,	  alpha	  tocopherol,	  
ascorbate	  
human Kaddurah-­‐Daouk	  et	  al.,	  2013 CSF n=38	  controls	  n=40	  patients LCECA	  HPLC UP:	  methionine,	  5-­‐hydroxyindoleacetic	  acid,	  vanillylmandelic	  acid,	  xanthosine,	  
gluthatione	  	  DOWN:	  gluthatione/methionine,	  	  5-­‐hydroxyindoleacetic	  acid/5-­‐
hydroxytryptophan
human Ibanez	  et	  al.	  2012 CSF n=85	  patients CE-­‐MS UP:	  choline,	  valine,	  serine	  	  	  DOWN:	  carnitine
human Czech	  et	  al.,	  2012 CSF n=51	  controls	  n=79	  patients GC-­‐MS	  LC-­‐MS/MS cysteine,	  tyrosine,	  phenylalanine,	  methionine,	  serine,	  pyruvate,	  taurine,	  creatinine,	  
cortisol,	  dopamine,	  uridine
human Oresic	  et	  al.,	  2011 plasma n=46	  controls	  n=47	  patients UPLC-­‐MS/GCxGC-­‐MS DOWN:	  ether	  phospholipids,	  phosphatidylcholines,	  sphingomyelins,	  sterols
human Han	  et	  al.,	  2011 plasma n=26	  controls	  n=26	  patients MDMS-­‐SL UP:	  ceramide	  (65	  sp.)	  DOWN:	  sphingomyelin	  (33	  sp.)
human Mapstone	  et	  al.,	  2014 plasma n=525	  participants MDMS-­‐SL serotonin,	  phenylalanine,	  proline,	  lysine,	  phosphatidylcholine	  (10	  sp.),	  taurine,	  
acylcarnitine	  
R6/2	  mouse	  model Tsang	  et	  al.	  2006b brain/plasma/urine n=10	  per	  group HR/HR-­‐MAS	  1H-­‐NMR	   Brain	  UP:	  creatine,	  glutamine,	  lactate	  DOWN:	  acetate,	  N-­‐acetyl-­‐aspartate,	  gamma-­‐
aminobutyric	  acid,	  choline	  Plasma	  UP:	  glucose,	  unsaturated	  lipids,	  creatine	  DOWN:	  
glutamate	  Urine	  UP:	  glucose,	  acetate,	  citrate,	  glycine,	  2-­‐oxoglutarate,	  succinate	  
trimethylamine	  N	  oxide	  DOWN:	  alpha-­‐ketoisocaproate,	  dimethylglycine,	  lactate,	  
spermine,	  trimethylamine
3-­‐Nitropropionic	  acid	  rat	  model Tsang	  et	  al.	  2009 brain n=5	  per	  group HR-­‐MAS	  1H-­‐NMR UP:	  succinate	  	  DOWN:	  taurine,	  gamma-­‐aminobutyric	  acid,	  creatine,	  N-­‐acetyl-­‐
aspartate,	  choline
HD-­‐N171-­‐N82Q	  mouse Underwood	  et	  al.,	  	  2005 plasma n=10	  per	  group GC-­‐TOF-­‐MS glycerol,	  glucose,	  monosaccharides,	  lactate,	  urea,	  malonate,	  valine,	  pyroglutamate
human Underwood	  et	  al.,	  	  2005 plasma n=20	  controls	  n=30	  patients GC-­‐TOF-­‐MS glycerol,	  monosaccharides,	  lactate,	  alanine,	  leucine,	  2-­‐amino-­‐N-­‐butyrate,	  ethylene	  
glycol,	  alpha-­‐hydroxybutyric	  acid,	  valine,	  malonate,	  urea
human	   Mochel	  et	  al.,	  2010 plasma n=32	  samples HR	  1H-­‐NMR DOWN:	  valine,	  leucine,	  isoleucine
human Bogdanov	  et	  al.	  2008 plasma n=25	  controls	  n=66	  patients LCECA	  HPLC UP:	  glutathione,	  	  2-­‐hydroxy-­‐2-­‐deoxyguanosine	  DOWN:	  uric	  acid
human	   Johansen	  et	  al.,	  2009 plasma n=15	  controls	  n=41	  patients LCECA	  HPLC DOWN:	  hypoxanthine,	  	  uric	  acid,	  hypoxanthine/xanthosine,	  xanthosine/xanthine,	  
hypoxanthine/uric	  acid
MOTOR	  NEURON	  
DISEASES
Spinocerebellar	  Ataxia MJDI	  mouse	  model	   Griffin	  et	  al.	  2004 brain n=5	  per	  group HR/HR-­‐MAS	  1H-­‐NMR	   UP:	  glutamine	  DOWN:	  gamma-­‐aminobutyric	  acid,	  choline,	  phosphocholine,	  lactate
human Blasco	  et	  al.,	  2013 CSF n=128	  controls	  n=66	  patients LC	  MS UP:	  pyruvate,	  ascorbate,	  acetone	  DOWN:	  acetate
human Kumar	  et	  al.,	  2010 plasma n=30	  controls	  n=25	  controls HR	  1H-­‐NMR UP:	  glutamate,	  acetate,	  acetone,	  beta-­‐hydroxybutyrate,	  formate	  DOWN:	  glutamine,	  
histamine,	  N-­‐acetyl	  derivatives
Motor	  Neuron	  Disease human	   Blasco	  et	  al.,	  2014 CSF n=86	  controls	  n=95	  patients HR	  1H-­‐NMR 2-­‐hydroxy-­‐isovaleric	  acid,	  valine,	  isoleucine,	  2-­‐oxo-­‐3-­‐methyl	  isovaleric	  acid,	  2-­‐
oxoisovaleric	  acid,	  isobutyric	  acid,	  threonine,	  tyrosine,	  phenylalanine,	  1-­‐methyl-­‐
histidine,	  histidine
CUMS	  model Chen	  et	  al.,	  2014 brain n=8	  per	  group GC-­‐MS UP:	  N-­‐acetylaspartate,	  β-­‐alanine	  DOWN:	  isoleucine,	  glycerol
human Kaddurah-­‐Daouk	  et	  al.	  2012 CSF n=18	  controls	  n=14	  depressed	  
n=14	  remitted
LCECA	  HPLC UP:	  5-­‐hydroxyindoleacetic	  acid,	  tyrosine/hydroxyphenyllactate,	  methionine,	  
glutathione/methionine,	  xanthine/homovanillic	  acid,	  homovanillic	  acid/5-­‐
hydroxyindoleacetic	  acid	  	  DOWN:	  5-­‐hydroxyindoleacetic	  acid/tryptophane,	  5-­‐
hydroxyindoleacetic	  acid/kynurenine,	  xanthine	  methionine,	  	  homovanillic	  acid
MDD	  rat	  models Shi	  et	  al.,	  2013 plasma n=9	  per	  group HR	  1H-­‐NMR CUMS	  model	  UP:	  trimethylamine,	  aspartic	  acid,	  glutamate,	  acetoacetic	  acid,	  N-­‐acetyl	  
glycoproteins,	  	  β-­‐alanine,	  lactate,	  leucine,	  isoleucine,	  lipids	  DOWN:	  proline,	  β-­‐
hydroxybutyrate,	  valine;	  FST-­‐1d	  model	  DOWN:	  trimethylamine;	  FST-­‐14d	  model	  UP:	  α-­‐
glucose,	  β-­‐glucose,	  β-­‐hydroxybutyrate,	  valine,	  lipids	  
human Paige	  et	  al.,	  2007 plasma n=9	  controls	  n=10	  patients GC-­‐MS DOWN:	  gamma-­‐aminobutyric	  acid,	  stearate,	  3-­‐hydroxybutanoic	  acid,	  glycerol
human	  post	  mortem	   Lan	  et	  al.,	  2009 brain n=10	  controls	  n=10	  patients HR-­‐MAS	  1H-­‐NMR UP:	  lactate,	  phosphocholine,	  creatine,	  myo-­‐inositol,	  glutamate	  DOWN:	  
polyinsaturated	  lipids
human	  post	  mortem	   Schwarz	  et	  al.,	  2008 brain n=15	  controls	  n=15	  patients UPLC-­‐MS Grey	  matter:	  phosphatidylcholines	  (12	  sp.),	  palmitic	  acid,	  heptadecanoic	  acid,	  oleic	  
acid	  White	  matter:	  phosphatidylcholines	  (12	  sp.),	  linoleic	  acid,	  oleic	  acid,	  ceramides	  
(3	  sp.)	  Red	  blood	  cells:	  stearic	  acid,	  linoleic	  acid
human Sussulini	  et	  al.,	  2012 plasma n=25	  controls	  n=25	  patients HR	  1H-­‐NMR acetate,	  valine,	  proline,	  glutamate,	  glutamine,	  asparagine,	  lysine,	  choline,	  arginine,	  
proline,	  myo-­‐inositol,	  arginine,	  lipids	  (VLDL),	  lipoproteins,	  lactate,	  acetate
phencyclidine	  rat	  model Weisseling	  et	  al.,	  2013 brain n=8	  per	  group HR	  1H-­‐NMR DOWN:	  choline,	  glutamine,	  glutamate,	  glycine,	  taurine
human	  post	  mortem	   Prabakaran	  et	  al.	  2004 brain n=10	  controls	  n=10	  patients HR-­‐MAS	  1H-­‐NMR Prefrontal	  cortex	  UP:	  lipid,	  taurine,	  glutamate/glutamine,	  lactate	  DOWN:	  adenosine,	  
uridine,	  myo-­‐inositol,	  phosphocholine,	  acetate,	  gamma-­‐aminobutyric	  acid
human	  post	  mortem	   Schwarz	  et	  al.,	  2008 brain/red	  blood	  cells n=15	  controls	  n=15	  patients UPLC-­‐MS Grey	  matter:	  phosphatidylcholines	  (10	  sp.),	  palmitic	  acid,	  stearic	  acid	  White	  matter:	  
phosphatidylcholines	  (6	  sp.),	  palmitic	  acid,	  stearic	  acid,	  heptadecanoic	  acid,	  oleic	  
acid,	  ceramides	  (3	  sp.)	  Red	  blood	  cells:	  DOWN:	  stearic	  acid,	  linoleic	  acid,	  arachidonic	  
acid,	  ceramide	  (1	  sp.),	  palmitic	  acid,	  oleic	  acid
human	  post	  mortem	   Chan	  et	  al.,	  2011 brain n=10	  controls	  n=10	  patients LC-­‐MS Prefrontal	  cortex	  UP:	  glutamine,	  creatine	  DOWN:	  valine,	  leucine,	  isoleucine,	  alanine
human	   Holmes	  et	  al.	  2006a CSF n=70	  controls	  n=37	  (cohort	  1)	  
n=17	  (cohort	  2)	  patients
HR	  1H-­‐NMR UP:	  glucose	  DOWN:	  acetate,	  lactate,	  glutamine	  (pH	  shift),	  alanine	  (pH	  shift)
human	   Cai	  et	  al.	  2012 plasma/urine n=11	  controls	  n=11	  patients UPLC-­‐MS/	  HR	  1H-­‐NMR Plasma	  UP:	  lactate,	  alanine,	  glycine,	  lysophosphatidylcholine	  (4	  sp.)	  DOWN:	  
lipoproteins,	  3-­‐hydroxybutyrate,	  phosphatidylcholine	  (1	  sp.),	  acetoacetate,	  glucose,	  
LDL/VLDL/HDL,	  	  uric	  acid,	  unsaturated	  fatty	  acids	  Urine	  UP:	  glycine,	  valine,	  glucose,	  
uric	  acid,	  pregnanediol	  DOWN:	  creatine,	  creatinine,	  taurine,	  hippurate,	  
trimethylamine-­‐N-­‐oxide,	  citrate,	  alpha-­‐ketoglutarate
human	   Yao	  et	  al.,	  2010a,	  2010b plasma n=30	  controls	  n=25	  patients LCECA	  HPLC UP:	  xanthosine/guanine,	  N-­‐acetylserotonin,	  N-­‐acetylserotonin/tryptophane,	  
melatonin/serotonin	  DOWN:	  guanine/guanosine,	  	  uric	  acid/guanosine,	  uric	  
acid/xanthosine,	  melatonin/N-­‐acetylserotonin
Rett	  Syndrome Mecp2-­‐KO	  mouse	  model	   Viola	  et	  al.,	  2007 brain n=4	  per	  group HR	  1H-­‐NMR UP:	  glutamine	  DOWN:	  myo-­‐inositol,	  phosphocholine/	  glycerophosphocholine,	  
glutamine/glutamate
Fragile	  X	  Syndrome Fmr1-­‐KO	  mouse	  model	   Davidovic	  et	  al.,	  2011 brain n=10	  per	  group HR-­‐MAS	  1H-­‐NMR UP:	  acetotacetate,	  CH2-­‐CO/CH2-­‐CH2-­‐CH2-­‐CO,	  taurine,	  creatine,	  beta-­‐amino	  butyrat	  
DOWN:	  lactate,	  glutamine,	  gamma-­‐aminobutyric	  acid,	  N-­‐acetyl-­‐aspartate,	  glutamate,	  
myo-­‐inositol,	  aspartate,	  acetate,	  N,N,N-­‐trimethyl-­‐lysine,	  alanine,	  kynurenine,	  N-­‐alpha-­‐
acetylornithine,	  adenine,	  inosine,	  purine,	  ethanolamine
maternal	  immune	  activation	  
ASD	  mouse	  model	  
Hsiao	  et	  al.,	  2013 plasma n=10/group GC/LC-­‐MS UP:	  4-­‐ethylphenylsulfate,	  ribose	  DOWN:	  	  3-­‐methyl-­‐2-­‐oxovalerate,	  4-­‐methyl-­‐
oxopentanoate,	  	  glycylvaline,	  equolsulfate,	  eicosenoate,	  stearate,	  13-­‐
hydroxyoctadecadienoic	  acid,	  9-­‐hydroxyoctadecadienoic	  acid,	  octadecanedioate,	  12-­‐
hydroxyeicosatetraenoic	  acid,	  1-­‐palmitoylplasmenylethanolamine,	  1-­‐
stearoylglycerophosphoinositol
human Yap	  et	  al.,	  2010 urine n=34	  controls	  n=39	  patients HR	  1H-­‐NMR UP:	  acetate,	  dimethylamine,succinate,	  taurine,	  N-­‐methyl	  nicotinic	  acid,	  N-­‐methyl	  
nicotinamide,	  N-­‐methyl-­‐2-­‐pyridone-­‐5-­‐carboxamide	  	  DOWN:	  glutamate,	  hippurate,	  
phenylacetylglutamine
human Emond	  et	  al.,	  2013 urine n=24	  controls	  n=26	  patients GC-­‐MS UP:	  succinate,	  glycolate	  DOWN:	  hippurate,	  3-­‐hydroxyphenylacetate,	  
vanillylhydracrylate,	  3-­‐hydroxy-­‐hippurate,	  p-­‐hydroxy	  mandelate,	  1H-­‐indole-­‐3-­‐acetate,	  
palmitate,	  stearate,	  3-­‐methyladipate
Down	  Syndrome human Bahado-­‐Singh	  et	  al.	  2013 1st	  trimester	  
pregnant	  woman	  
plasma
n=60	  controls	  n=30	  patients HR	  1H-­‐NMR UP:	  2-­‐/3-­‐hydroxybutyrate,	  	  2-­‐hydroxyisovalerate,	  acetamide	  acetone,	  carnitine,	  
lactate,	  pyruvate,	  L-­‐methylhistidine	  DOWN:	  dimethylamine,	  methionine
Neuronal	  Ceroid	  
Lipofuscinoses
Autism	  spectrum	  
disorders
Schizophrenia
Alzheimer's	  Disease
Huntington's	  Disease
Parkinson's	  Disease
Amyotrophic	  Lateral	  
Sclerosis
NEURODEVELOPMENTAL	  
DISORDERS
PSYCHIATRIC	  CONDITIONS
Bipolar	  Disorder
Major	  Depressive	  
Disorder
Salek	  et	  al.	  2010 HR	  1H-­‐NMR UP:	  lactate,	  aspartate,	  glycine,	  alanine,	  leucine,	  isoleucine,	  valine,	  fatty	  acids	  	  	  	  	  	  	  	  	  
DOWN:	  N-­‐acetylaspartate,	  glutamate,	  glutamine,	  taurine,	  gamma-­‐aminobutyric	  acid,	  
choline,	  phosphocholine,	  creatine,	  phosphocreatine,	  succinate
brain n=5	  per	  groupCRND8	  mouse	  model	  
Neurodevelopmental	  
disorders
Enriched	  metabolic	  pathway SMPDB	  or	  KEGG	  ID AD HD NCL MND MDD SCZ FXS
Alanine	  metabolism SMP00055 ✓ ✓ ✓
Alanine,	  aspartate	  and	  glutamate	  metabolism	   map00250 ✓ ✓
Arginine	  and	  proline	  metabolism	   SMP00020 ✓ ✓ ✓
Cysteine	  metabolism SMP00013 ✓
Glycine,	  serine	  and	  threonine	  metabolism map00260 ✓
Methionine	  metabolism SMP00033 ✓ ✓
Valine,	  leucine,	  isoleucine	  degradation SMP00032 ✓ ✓ ✓
Histidine	  metabolism SMP00044 ✓
D-­‐Glutamine	  and	  D-­‐glutamate	  metabolism map00471 ✓ ✓ ✓
Glutamate	  metabolism SMP00072 ✓ ✓ ✓
Catecholamine	  biosynthesis SMP00012 ✓
Tyrosine	  metabolism SMP00006 ✓
Phenylalanine	  and	  tyrosine	  metabolism SMP00008 ✓ ✓
Tryptophan	  metabolism SMP00063 ✓ ✓
Taurine	  and	  hypotaurine	  metabolism SMP00021 ✓
Gluconeogenesis SMP00128 ✓
Ketone	  body	  metabolism SMP00071 ✓
Pyruvate	  metabolism SMP00060 ✓ ✓
Urea	  cycle SMP00059 ✓
Pyrimidine	  metabolism SMP00046 ✓
Aminoacyl-­‐tRNA	  biosynthesis	   map00970 ✓
Ammonia	  recycling	   SMP00009 ✓ ✓
Betaine	  metabolism SMP00123 ✓
Neurodegenerative	  disorders Psychiatric	  disorders
Amino	  acids
Neurotransmitters	  
Energy	  substrates
Other



